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Synopsis 
This thesis investigates the management and prognosis of endometrial hyperplasia.  The 
literature on conservative therapies for endometrial hyperplasia is systematically reviewed 
and a meta-analysis is performed to identify the most effective treatment.  Further meta-
analysis is performed for young women with severe endometrial hyperplasia or cancer to 
explore the effectiveness of fertility-sparing treatment.  A national survey of Gynaecologists 
is performed to evaluate current and the need for further research.  A large cohort study is 
included that defines the regression and relapse of endometrial hyperplasia with two popular 
conservative therapies, the Levonorgestrel-releasing intrauterine system (LNG-IUS) and oral 
progestogens.  The LNG-IUS is found to induce regression more often with fewer events of 
relapse than oral progestogens.  A prediction model based on clinical characteristics and 
biomarkers finds that morbid obesity is an independent predictor for relapse.  This research 
has major implications for clinical practice and a national guideline in process is based on its 
findings.   
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Chapter 1: Introduction 
Introduction 
Endometrial hyperplasia (EH) is the precursor of endometrial carcinoma, which is the 
commonest gynaecological malignancy in the western world.
1
  In 2007 in England and 
Wales, 7,536 new cases of endometrial cancer (EC) were registered and, although, the 
incidence of EC is high, the incidence of EH is three times higher and it can progress to 
cancer if left untreated.
2,3
  EH is believed to produce a continuum of lesions that may be 
precursors to EC of endometrioid histology and require treatment for preventing progression.  
The EC is thought to be oestrogen-dependant and arise in a background of EH.
4
  It arises 
usually in peri-menopausal or menopausal women when oestrogen, unopposed by 
progesterone, stimulates endometrial cell growth by binding to oestrogen receptors in the 
nuclei of endometrial cells.    The risk factors for EH are the same as those for EC and 
include obesity, nulliparity, early menarche, late menopause, anovulatory cycles, Tamoxifen 
or hormone replacement therapy (HRT) use.  There is especially strong evidence that the use 
oestrogen-only HRT and obesity increase the risk for women developing EH.
5,6
   The most 
appropriate management of EH has been among the most controversial areas in gynaecology 
since it was known that while EH is not malignant, but a precursor of invasive cancer.
4
   
 
Classification of endometrial hyperplasia 
The World Health Organisation (WHO) categorises EH as simple (SH), complex (CH), 
simple atypical (SAH), or atypical complex (ACH) on the basis of architectural crowding and 
nuclear atypia.
7
  However, in contrast to SAH, most cases of atypical hyperplasia by 
definition, are characterised by a complex glandular architecture, glandular crowding, 
14 
 
epithelial cells showing the cytological hallmarks of malignancy and lack of endometrial 
stromal.  In a large prospective study, no case of SAH has been found.
7
  In accordance with 
others, we assume that this category, if it does exist, is extremely rare and its existence is 
disputed.
8,9 
 
As a result, the WHO classification can be confusing and a simpler classification of SH, CH 
and ACH has been proposed.
10
  SH is often considered a variation of normal endometrium 
and its risk of progression to cancer is comparable to the normal population (less than 1%).
4
  
CH has an intermediate risk of progression to cancer (about 3%) and can be treated with 
hormone therapies.
4
  ACH has a high risk of progression to cancer (up to 29%) and the 
possibility of concomitant cancer (up to 43%) in women undergoing hysterectomy.
4;11 
 
For the purposes of this thesis we shall classify endometrial hyperplasia as follows: 
1. Simple hyperplasia (SH) 
2. Complex Hyperplasia 
a) Without Atypia (CH) 
b) With Atypia (ACH) 
 
Molecular pathology 
Endometrial hyperplasia is considered to be an oestrogen-dependent benign disease of the 
endometrium with malignant potential.
4
  The key step to this transformation to the majority 
of the cases appears to be the local oestrogen production from androgens catalysed by the 
15 
 
aromatase enzyme.
12-14
  In fact, the aromatase enzyme is detectable in the majority of cases 
of endometrioid cancer, but not in endometrial hyperplasia.
12,15,16
  
 
PGE2 increases intracellular aromatase activity and stimulates oestrogen biosynthesis, and 
there is a strong linear association between aromatase and expression of cyclo-oxygenases in 
uterine and breast cancer specimens, resulting in a complex paracrine and/or autocrine 
signalling pathway effecting abnormal oestrogen synthesis.
13,17,18
  Cyclo-oxygenase (COX) is 
the rate-limiting enzyme in the prostaglandin biosynthetic pathway that stimulates oestrogen 
biosynthesis and higher COX-2 expression has been reported in hyperplastic or malignant 
endometrium than in normal.
12,16,17,19
  COX-2 is significantly associated with aromatase 
expression in endometrial cancer,
12
 which suggests that intra-endometrial oestrogen 
production promotes progression of endometrial hyperplasia to cancer.  Recently, the use of 
aromatase inhibitors has been advocated for endometrial hyperplasia and cancer
20-22
 and the 
beneficial potential of COX-2 inhibitors has been widely described,
23,24
 but not applied in 
clinical practice. In conclusion, the assessment of aromatase/COX-2 activity and steroid 
receptor status is potentially a key marker for targeted hormonal treatment of endometrial 
lesions when diagnosed early during cancerogenesis. 
 
The abnormalities in the oestrogen pathway are not the only causative features for 
endometrial hyperplasia and its malignant potential. The angiogenesis, inhibition of apoptosis 
and DNA mismatch-repair mechanism or activation of oncogenes are the pathways most 
commonly described to be involved in endometrial hyperplasia. For example, cyclo-
oxygenase plays a major role in endothelial cell migration and is implicated in the production 
16 
 
of pro-angiogenic factors, such as Vascular Endothelial Growth Factor (VEGF) and 
consequent promotion of endometrial angiogenesis.
19
 VEGF production is found to be 
stimulated by oestrogen concentration and is strongly correlated with the microvessel 
count.
19,25
 It has been shown that the altered expression of proteins i.e. bcl-2, PTEN may play 
an important role by affecting apoptosis of hyperplastic cells.
26,27
 The abnormal methylation 
of MLH1 is the commonest event in endometrial hyperplasia that generates microsatellite 
instability (MSI) due to defects of the DNA mismatch-repair mechanism.
25
  Oestrogens may 
increase the rate of mutagenesis of MLH1 through free radical formation as well as its 
inherent proliferative influence.
25
  The combination of these pathways seems to orchestrate 
the progression of endometrial hyperplasia to cancer with oestrogens to mastermind the 
process.  The expression analysis of the above biomarkers currently helps understand the 
pathogenesis of endometrial hyperplasia and the pathways involved during this process. 
However, their utility as predictors for response to progestogen treatment has not been 
extensively studied yet. 
 
 
Management of EH 
Management of SH 
On the management of SH the literature is scarce.  The study by Kurman et al is often cited 
and is unique in the literature because it has followed up 93 women with SH for more than 26 
years that did not have any treatment.
4
  Only one woman, less than 30 years old, progressed 
to EC.  Interestingly, 81% of the women regressed to normal with no treatment.  Hence, the 
German Working Group of Gynecologic Oncology suggests that this condition can also be 
managed expectantly.  Taking into account that EC lifetime risk is about 3% and this 
17 
 
condition affect women over 50 years of age, it appears that their risk is not much higher than 
that of the normal population.
28  
However, clinicians may opt to treat this condition for 
symptomatic relief of abnormal uterine bleeding. This is the main reason in Chapter 2 we 
summarise the literature and also compare the efficacy of available therapies for the different 
types of hyperplasia. 
 
Management of CH 
CH has a low risk of progression to EC, which can take up to 10 years.
4
  An evaluation of 
current practice in treating CH found that most women are managed with hysterectomy.
29 
 
Despite this, medical treatment with progestogens is shown to induce regression in a 
significant proportion of these women.
29 
 Traditionally, oral progestogens have been used to 
treat this condition for inducing regression of CH and reduce the risk of progression to cancer 
up to 3-fold.
30
  Recently, the LNG-IUS has also been used for this purpose.
31
  In a previous 
study the difference in efficacy between LNG-IUS and oral progestogens has been 
investigated, but the outcomes were not reported using the widely accepted WHO criteria and 
therefore were difficult to interpret.
32
  The progestogen concentrations in the uterine mucosa 
when delivered through an intrauterine device, directly into the cavity are reported to exceed 
that of the oral treatment by several-fold.
33
  The intrauterine progestogen release is also 
associated with higher patient satisfaction and, therefore patients are more likely to continue 
the treatment.  This higher chance of patients continuing the LNG-IUS treatment resulting in 
higher compliance may also explain its better efficacy in treating endometrial hyperplasia 
compared with oral progestogens. 
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Management of ACH 
Women with ACH are at high risk of progressing to cancer or already have underlying cancer 
while undergoing hysterectomy.
4;11 
 In the majority of the cases women are advised to 
undergo hysterectomy because of the malignancy risk.
29 
 However, young women with strong 
fertility desires and women with multiple comorbidities may not be good surgical candidates.  
There have been some reports of successful therapy with progestogens of ACH and even 
well-differentiated EC.
34,35
  A small percentage of women successfully got pregnant and 
achieved live births during follow up either with spontaneous conception or with assisted 
reproductive techniques.
34
  However, the feasibility of this treatment option has not been 
thoroughly investigated and its safety remains a concern. 
 
Prognosis of endometrial hyperplasia 
In an important paper, Ferenczy et al reported on 85 women with endometrial hyperplasia 
who were treated with oral progestogens.
36
  The patients who had no evidence of cytological 
atypia achieved a higher rate of endometrial regression compared to the patients with cellular 
atypia (86% vs 50%) and recurrence of hyperplasia was less frequent (6% vs 50%).
36
  The 
likelihood of response to hormonal therapy was directly related to the absence of cytological 
atypia and this is the only marker that is currently used for predicting progestogen response.  
Patient clinical characteristics such as age, body mass index (BMI), diabetes, hypertension 
and menopausal status are found to be associated with endometrial hyperplasia.  However, 
currently no studies have evaluated their impact on predicting therapeutic success following 
progestogen treatment.  While one might anticipate that response to progestogens would be 
predicted by the steroid receptor status of the hyperplastic endometrium this is not proven.  
19 
 
Both oestrogen (ER) and progesterone (PR) receptors are present in high levels in 
hyperplastic endometria but studies have repeatedly failed to show a relationship between 
receptor status and response to progestogens.
37-39
  This has biological plausibility but many 
research groups have tried to correlate these biomarkers with outcome in hyperplasia when 
treated with oral progestogens.
37-39
  This is problematic because compliance is an issue with 
oral progestogens and introduces significant unmeasured confounding.  The difficulty in 
measuring this parameter means that inferences cannot be adjusted for this essential 
parameter.  Other molecular pathways have also been investigated with some recording 
promising results.
40
  These are discussed more in detail in Chapters 7 and 9.  The fact is that 
the accurate stratification of risk will help clinicians follow up adequately these patients at 
risk of progressive/persistent disease and reassure those with low risk.  Consequently, we 
believe this will reduce unnecessary surgical interventions and NHS costs. 
 
Aims & Objectives of this thesis 
My thesis aims to investigate and improve the management and prognosis of women with EH 
through the following eight objectives: 
1. To evaluate the regression rate with oral progestogens and LNG-IUS for women with 
EH, compare these two main medical therapies and identify the most effective treatment 
option in the published literature. 
2. To evaluate the regression, relapse, and live birth rates of early-stage EC and ACH 
with fertility-sparing treatment in the published literature. 
3. To determine current practice for the management of endometrial hyperplasia through 
a national survey.  
20 
 
4. To compare the regression rate of the LNG-IUS versus oral progestogens for the 
treatment of women with EH in a cohort study. 
5. To determine the risk of relapse for women with EH treated with LNG-IUS or oral 
progestogens in a cohort study. 
6. To explore the prognostic ability of ER and PR, phosphatase and tensin homolog 
(PTEN) and aromatase to predict persistent EH when treated with LNG-IUS in a case-control 
study. 
7. To identify clinical predictors for regression and relapse of EH treated with LNG-IUS 
or oral progestogens. 
8. To test the predictive ability of ER, PR, COX-2, Mlh1, and Bcl-2 expression for 
predicting the outcomes of regression and relapse in women with EH treated with LNG-IUS.  
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SECTION I MANAGEMENT OF ENDOMETRIAL HYPERPLASIA 
Chapter 2: Oral progestogens versus LNG-IUS for EH: a systematic 
review and meta-analysis.  
Abstract 
Objective  
To conduct a systematic review and meta-analysis of studies evaluating the regression rate of 
EH with oral progestogens and LNG-IUS. 
Methods  
Searches were conducted on Medline, Embase, Cochrane Library, and Web of Science, and 
reference lists of relevant articles were examined. The methodologic index for non-
randomised studies was used for quality assessment. Meta-analysis was performed with 
random effects model. 
Results  
There were 24 observational studies (1001 women), of low methodologic quality, evaluating 
the outcome of regression of EH with oral progestogens or LNG-IUS. Meta-analysis showed 
that oral progestogens achieved a lower pooled regression rate compared with LNG-IUS for 
CH (pooled rate, 66% vs 92%; P=0.01) and ACH (pooled rate, 69% vs 90%; p=0.03). There 
was no statistical difference in SH (pooled rate, 89% vs 96%; p=0.41). 
Conclusion  
Oral progestogens appear to induce a lower disease regression rate than LNG-IUS in the 
treatment of EH. 
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Introduction 
EH is a common diagnosis (5-10%) in women presenting with abnormal uterine bleeding, 
and can progress to cancer if left untreated.
4
  The risk of progression of endometrial 
hyperplasia to cancer is dependent on the histological diagnosis.  The risk of cancer 
progression is low for women with CH compared to women with ACH.
4
  Currently, there are 
no professional body guidelines for the management of EH.  The use of progestogens, which 
antagonise the oestrogen effect on the endometrium, can induce endometrial regression and 
prevent progression to cancer.
4
  The main oral progestogens used to treat EH are 
Norethisterone Acetate, Megestrol Acetate and Medroxyprogesterone 17-Acetate.  More 
recently, the LNG-IUS developed primarily as a contraceptive device, has also been used 
successfully to treat EH.
31
   These strategies, if successful could reduce the number of 
hysterectomies performed for this condition and hence reduce morbidity and healthcare costs.  
Against this background, we conducted a systematic review of studies evaluating oral and 
intrauterine progestogens for the treatment of EH and meta-analysed their treatment effects.  
 
Methods 
Identification of literature 
The population of interest in this systematic review was women with EH, the intervention 
was treatment with oral progestogens, the comparison was LNG-IUS and the outcome was 
evidence of disease regression or persistence.  The following electronic databases were 
searched: MEDLINE (1950 to December 2009), EMBASE (1980 to December 2009), 
Cochrane Central Register of Controlled Trials and Web of Science conference proceedings 
(ISI Proceedings, 1990 to December 2009).  A combination of Medical Subject Headings 
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(MeSH) and text words were used to generate two subsets of citations, one including studies 
of EH (“endometr* hyperplas*”, “premalignant endometr*”, “precancer* endometr*”) and 
the other including studies of progestogens and intrauterine devices or systems (“intrauterine 
devices medicated”, “Levonorgestrel”, “mirena”, “intrauterine progest*”, “LNG-IU*”, 
“progest*”, “gestag*”).  These subsets were combined with “AND” and limited to “Humans 
and Female” to generate a subset of citations relevant to our research question.  The reference 
lists of all known primary and review articles were examined to identify cited articles not 
captured by electronic searches.  Language or geographical restrictions were not applied 
during search or selection.  The searches were conducted independently by two reviewers. 
 
Study selection and data extraction 
Studies were selected if the participants were women diagnosed histologically with EH, the 
intervention was treatment with either oral progestogens or LNG-IUS and the outcome was 
histological disease regression rates, as assessed on endometrial biopsy or hysterectomy 
specimen.  Both controlled and uncontrolled designs were included.  Case reports or series 
with less than five cases were excluded.  Studies reporting on women with EH treated with 
other form of progestogens than oral or LNG-IUS (e.g. injectable, pessaries) were excluded.  
Studies classifying women with EH in other than the WHO classification
7
 were also 
excluded.  
 
Studies were selected in a two-stage process.  First, the titles and abstracts from the electronic 
searches were scrutinised by two reviewers independently and full manuscripts of all 
citations that met the predefined selection criteria were obtained.  Secondly, final inclusion or 
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exclusion decisions were made on examination of the full manuscripts.  In cases of 
duplicates, the most recent or the most complete publication was used.  Any disagreements 
about inclusion were resolved by consensus or arbitration by a third reviewer. 
 
Two reviewers completed the quality assessment.  The Methodological Index for Non-
Randomised Studies (MINORS), which assesses the quality of the included studies, was 
implemented.
41
  Items assessed included selection of cases or cohorts and controls, 
comparability and information on exposure and outcome.  This index was preferred over 
Newcastle-Ottawa Quality Assessment Scale
42
 as we included studies without a control 
group and the MINORS checklist allows a quality evaluation in studies with and without a 
control group.  From each study, outcome data were extracted in 2x2 tables by the two 
reviewers.  No ethical approval was sought for this study as it was a systematic review and 
meta-analysis of published manuscripts.   
 
Statistical analysis 
Regression rates from individual studies were meta-analysed using random effects model.
43
  
Heterogeneity of the exposure effects was statistically analysed using the chi-squared test.
44
  
Exploration of the causes of heterogeneity was planned using variation in features of 
population, exposure and study quality.
45
  The regression rates between the two interventions 
were compared with the aid of meta-regression.  Statistical analyses were performed using 
Stata 8.0 (Stata Corp, TX, USA). 
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Results 
The search strategy yielded 2203 citations all captured from electronic citations.  Of these, 
2157 were excluded as it was clear from the title and abstract that they did not fulfil the 
selection criteria.  Examination of the full manuscripts of the remaining 46 articles found that 
three studies lacked original data (e.g. reviews or letters), one study was a duplicate and 18 
studies did not meet the selection criteria.  Thus a total of 24 primary studies, including 1001 
women with EH were selected for this review
18-31;34;46-64
 (Figure 1).   
Figure 1 Study selection process for systematic review of oral and intrauterine progestogens for the treatment of EH 
 
The longest follow-up period was eight years.  Fifteen studies were case series and nine were 
controlled studies.  The main characteristics of the 24 studies and the MINORS Index are 
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presented in Table 1.  Although all studies included women with either oral progestogens or 
LNG-IUS, the type, dose, regimen and duration of treatment varied.  The type of EH (SH, 
CH or ACH) treated also varied between the different studies.  Most studies were judged to 
be of poor quality on the MINORS index (Figure 2), with particular low scores for 
prospective calculation of the study size, prospective recruitment and biased assessment of 
regression rates.     
Figure 2 Quality checklist 
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Table 1 Characteristics of the studies included in the systematic review of oral and intrauterine progestogens for the 
treatment of EH. 
Author
-Year Type of study Study population Intervention or study groups Outcome and follow up 
Bese-
2006
 
(n=37) 
Matched 
controlled study 
Simple hyperplasia (n = 19) and matched 
controls without hyperplasia (n=18) 
Norethisterone 15mg/day for 10 days 
between the 16th and 25th day for 3 
months
 
Outcome: Histological response 
at 3 months, proliferative and 
apoptotic activity 
Follow up: 3 months  
Buttini-
2009
 
(n=57) 
Retrospective 
comparative 
study 
Women with simple (n=33), complex 
(n=8) or atypical hyperplasia (n=16) 
Oral progestogens, usually 
Medroxyprogesterone 10-20mg/day of 
unreported duration and regimen (n=10), 
LNG-IUS
a
 followed by hysterectomy 
(n=7), LNG-IUS
a
 alone (n=19) and 
hysterectomy alone (n=21)  
Outcome: Histological response 
at 6 months and menstrual 
function 
Follow up: Variable, range 6-69 
months 
Clark-
2006 
(n=281) 
Retrospective 
comparative 
study 
Women with simple (n=55), complex 
(n=173) or atypical hyperplasia (n=53) 
Excluded: Women with incidental 
finding of hyperplasia diagnoses on 
hysterectomy specimens  
Oral progestogens of unreported type, 
dose, duration and regimen (n=77),  
LNG-IUS
a
 (n=29), HRT
b
 (n=2), other 
medical (n=2), endometrial ablation 
(n=2), hysterectomy (n=109), 
observation only (n=60) 
Outcome: Histological and 
clinical response 
Follow up: Mean of 36 months, 
range 24-48 
Guven-
2001 
(n=27) 
Case series 
study 
Women with simple (n=16), complex 
(n=5) or atypical hyperplasia (n=3) 
Megestrol 160-320mg/day for 3 months 
(n=22), 45 days (n=2), or 60 days (n=3) 
Outcome: Histological response 
every 3-6 months 
Follow up: Not reported 
Haimov
ich-
2008 
(n=15) 
Prospective case 
series study 
Women with simple hyperplasia (n=15) 
Excluded: Women with uterine 
hypertrophy or sub-mucosal myomas 
LNG-IUS
a
 for 24 months Outcome: Histological response 
and bleeding pattern at 3, 6, 12 
and 24 months 
Follow up: 24 months 
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Horn-
2004 
(n=502) 
Retrospective 
controlled study 
Women with complex (n=208) or 
atypical hyperplasia (n=7) that received 
progestogens and women treated without 
progestogens (n=287) 
Excluded: Women with no clinical data 
regarding follow up, women re-classified 
into simple hyperplasia  after histological 
re-examination and women with 
synchronous cancer 
Medroxyprogesterone or Norethisterone 
for 3-5 months. Norethisterone 5mg/day  
for pre-menopausal women, 
Medroxyprogesterone 10mg/day for 
perimenopausal women and 20-
50mg/day for postmenopausal women 
(n=215) 
 
Outcome: Histological response 
at a median of 4.8 months, range 
3-22 
Follow up: Not reported 
Jarvela-
2005 
(n=34) 
Oral 
progestogen arm 
of a randomised 
controlled trial 
Women with simple (n=16) or complex 
hyperplasia (n=1) that received 
progestogens and women treated with 
thermal balloon endometrial ablation 
(n=17) 
Excluded: Women with previous 
progestogen use, signs of atypical 
hyperplasia, pregnancy, desire for 
fertility, fibroids>3cm or distorting the 
uterine cavity, genital infections, 
malignancy or previous endometrial 
ablation 
Group 1) For pre-menopausal women, 
Medroxyprogesterone 10mg/day from 
day 15 to 24 for 3 months and for post-
menopausal women 
Medroxyprogesterone, 10mg/day for 3 
months (n=17) 
Group 2) Endometrial ablation (n=17) 
Outcome: Histological response, 
clinical and ultrasound 
examination at 6 and 12 months 
Follow up: Not reported 
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Jobo-
2001 
(n=53) 
Retrospective 
comparative 
study 
Women with complex aypical 
hyperplasia (n=53) 
Excluded: Women that refused 
treatment and follow up 
Group 1) Medroxyprogesterone acetate 
10mg for 14 days/cycle for 6 months 
(n=8), 
Group 2)  Medroxyprogesterone acetate 
400mg/day for 6 months (n=12) 
hysterectomy (n=30) and observation 
only (n=2) 
Outcome: Histological response 
at 10.8 weeks (4-30) for group 1 
and 7.3 (3-15) weeks for group 
2  
Follow up: Mean of 66 months, 
range 8-281 
Kaku-
2001 
(n=30) 
Retrospective 
case series 
Women with atypical hyperplasia (n=18) 
or endometrial carcinoma (n=12) wishing 
to preserve their fertility  
Excluded: Women were excluded if 
found not to have atypical hyperplasia or 
endometrial carcinoma after pathological 
review, women were excluded if follow 
up specimens were not available 
Medroxyprogesterone 100-600mg/day 
for 1-23 months for endometrial 
hyperplasia and 200-800mg/day for 2-14 
months for endometrial cancer 
Outcome: Histological response 
and pregnancy rates every 1-4 
months 
Follow up: Median of 31.5 
months, range 10-133 
Milam-
2008 
(n=38) 
Retrospective 
case series study 
Women with matched pre-progesterone 
and post-progesterone treated pairs of 
endometrial biopsies with endometrial 
hyperplasia (n=38) 
Excluded: Women with disagreement of 
diagnosis of endometrial hyperplasia 
after histological re-evaluation and when 
there was limited material for 
immunohistochemical evaluation 
Medroxyprogesterone, Megestrol or 
Norethisterone for a median of 3 months 
(1-12 months) of unreported dose and 
regimen 
Outcome: Histological and 
immunohistochemical response 
Follow up: Not reported 
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Minagu
chi-
2007 
(n=31) 
Case series 
study 
Women with atypical complex 
hyperplasia (n=12) or Stage IaG1 
carcinoma (n=19) who wished to 
preserve fertility or could not receive 
surgery due to complications 
Excluded: Women over the age of 40 
and those who did not attempt to 
conceive 
Medroxyprogesterone 2.5mg-600mg/day 
for 3-18 months, mostly 400-600mg/day 
for 6 months  
Outcome: Histological and 
immunohistochemical response 
every 2-4 months , pregnancy 
and hysterectomy rates  
Follow up: Median of 40.7 
months, range 2-109 
Randall
-1997 
(n=67) 
Retrospective 
case series study 
Women under age of 40 with atypical 
hyperplasia (n=32) or well-differentiated 
carcinoma (n=35) 
Excluded: Women that declined 
treatment and any follow up and women 
that declined treatment and endometrial 
sampling 
Oral progestogens Medroxyprogesterone 
10-30mg/day for 3-12 months or 
Megestrol 40-160mg/day for 3-12 
months (n=29), ovulation induction 
(n=2), Bromocriptine (n=1), oral 
contraceptive (n=1), hysterectomy 
(n=27) 
Outcome: Histological response 
at 3-6 months, pregnancy and 
hysterectomy rates  
Follow up: Mean of 40 months, 
range 9-79 
Rattana
chaiyan
ont-
2005 
(n=134) 
Prospective case 
series study 
Women with simple (n=116) or complex 
(n=18) hyperplasia that completed a 
cycle of progestogens 
Excluded: Women not having 
progestogen therapy , not having data on 
endometrial histology, loss to follow up, 
pregnancy, amenorrhea 
Mainly cyclic Medroxyprogesterone 
10mg/day and Norethisterone 10mg/day 
for 12-14 consecutive days per month for 
6 months 
Outcome: Histological response 
at 4, 16 and 24 weeks, vaginal 
bleeding pattern and associated 
pelvic pathology  
Follow up: Not reported 
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Reed-
2009
 
(n=185) 
Retrospective 
case series study 
Women older than 18 with complex 
(n=115) or atypical (n=70) hyperplasia 
after central pathology review and with 
an additional pathological specimen 8 
weeks to 6 months after index diagnosis 
Excluded: Women with follow-up 
specimen not available or not diagnostic,  
dispensed more than 14 days of 
oestrogen and less than 14 days of 
progestogen dispensed 
Medroxyprogesterone (n=66), Megestrol 
(n=61) or Norethisterone (n=11) at 
different doses for 14 days up to 6 
months and observation only (n=38) 
Outcome: Histological response 
at 8 weeks up to 6 months 
Follow up: Mean of 16.4 weeks, 
range 8-26 
 
Signore
lli-2009 
(n=21) 
Prospective case 
series study 
Women under the age of 40 with atypical 
hyperplasia (n=10) or endometrial cancer 
(n=11) wishing fertility potential 
Cyclical natural progesterone 200 mg 
daily from day 14 to day 25 (n=21) 
Outcome: Histological response 
and pregnancy rate every 3 
months  
Follow up: Median of 98 
months, range 35-176 
Tjalma-
2004
 
(n=8) 
Case series 
study 
Women with atypical hyperplasia (n=7) 
and with endometrial cancer (n=1) 
LNG-IUS
a
  Outcome: Histological and 
immunohistochemical response 
at 3-6 months  
Follow up: Mean of 29 months, 
range 11-51 
Varma-
2008
 
(n=105) 
Prospective 
cohort study 
Women with simple (n=16), complex 
(n=80) and atypical hyperplasia (n=9) 
LNG-IUS
a 
Outcome: Histological response, 
hysterectomy and cancer rates at 
3, 6, 12, 18, 24 months 
Follow up: Not reported 
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Vereide
-2006 
(n=50) 
Prospective 
cohort study 
Women with simple (n=26), complex 
(n=11) and atypical (n=13) hyperplasia 
LNG-IUS
a
 (n=21) and oral 
Medroxyprogesterone 10mg for 10 days 
per cycle for 3 months (n=29) 
Histological and 
immunohistochemical response 
at 3 months 
Follow up: Not reported 
Wheele
r-2007
 
(n=44) 
Retrospective 
cohort study 
Women with atypical hyperplasia (n=18) 
or well-differentiated endometrial cancer 
(n=26) 
Oral progestogens of unreported type, 
dose and duration (n=29) or 
progesterone-releasing intrauterine 
device (n=15) 
Outcome: Histological response 
at 1-3, 4-6 and 7-9 months 
Follow up: Median of 11 
months, range was not reported 
Wilder
meersc
h-2007 
(n=20) 
Prospective 
cohort study 
Women with simple (n=12) or atypical 
hyperplasia (n=8) 
LNG-IUS
a
 14 µg releasing (n=7) for 3 
years, replaced by a 20µg releasing 
LNG-IUS
a
 (n=13) 
Outcome: Histological response 
and ultrasound endometrial 
thickness  
Follow up: Mean of 36 months, 
range 14-90 
Witkie
wicz-
2010 
(n=15) 
Retrospective 
case series 
Women with atypical hyperplasia (n=7) 
or well-differentiated carcinoma (n=8) 
Megestrol for a mean of 13.3 months 
(n=11), Megestrol + IUD
c 
for a mean of 
31 months (n=2), Megestrol + 
Medroxyprogesterone for 20 months 
(n=1), Megestrol + IUD
c
 + Depot 
Medroxyprogesterone for 33 months 
(n=1).  Doses of oral progestogens were 
not reported. 
Outcome: Histological and 
immunohistochemical response 
Follow up: Not reported 
Yener-
1997 
(n=30) 
Oral 
progestogens 
arm of a 
randomised 
controlled study 
Women with simple hyperplasia (n=30) Medroxyprogesterone 20mg/day from 
day 16 to day 25 for 3 months (n=15) and 
Depot Goserelin subcutaneous implant 
each 28 days for 3 times (n=15) 
Outcome: Histological response 
at 3 months 
Follow up: Not reported 
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Yu-
2009 
(n=25) 
Retrospective 
cohort study 
Women under age of 35 with severe 
atypical hyperplasia (n=17) or 
endometrial carcinoma (n=8) 
Medroxyprogesterone 250-500mg/day 
for endometrial carcinoma and 100-
500mg/day for atypical hyperplasia 
(n=22) or Megestrol Acetate or 
Hydroxyprogesterone Caproate of 
unreported dose (n=3), all continued for 
at least 3-6 months after remission 
Outcome: Histological response 
at intervals of 3 months  
Follow up: Mean of 34.6 
months, range 7-114 
 
Regression outcomes for SH 
Meta-analysis of the nine studies (213 women) of women with SH treated with oral 
progestogens showed a pooled regression rate of 89% (95% CI 77-100%) (Figure 3).  
Pooling the six studies (72 women) of women with SH treated with LNG-IUS found a pooled 
regression rate of 96% (95% CI 76-100).  Meta-regression showed that the pooled regression 
rates were not statistically significantly different (p=0.41).  The p value for the χ2 test for 
heterogeneity was 0.95 for oral progestogens and 0.99 for LNG-IUS, indicating little 
variability in regression rates for these studies. 
 
Regression outcomes for CH 
Meta-analysis of the nine studies (389 women) of women with CH treated with oral 
progestogens showed a pooled regression rate of 66% (95% CI 58-74%).  Pooling the four 
studies (102 women) of women with CH treated with LNG-IUS found a pooled regression 
rate of 92% (95% CI 65-100%).  Meta-regression showed that the pooled regression rates 
were statistically significantly different (p<0.01).  The p value for the χ2 test for heterogeneity 
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was 0.86 for the oral progestogens and 0.99 for LNG-IUS, indicating little heterogeneity in 
the pooled regression rates. 
 
Regression outcomes for ACH 
Meta-analysis of the 14 studies (189 women) of women with ACH treated with oral 
progestogens showed a pooled regression rate of 69% (95% CI 58-83%).  Pooling the seven 
studies (36 women) of women with ACH treated with LNG-IUS found a pooled regression 
rate of 90% (95% CI 62-100).  The pooled regression rates were statistically significantly 
different (p=0.03).  The p value for the χ2 test for heterogeneity was 0.60 for the oral 
progestogens and 0.99 for LNG-IUS, indicating little heterogeneity in the pooled regression. 
Figure 3 Meta-analysis of studies 
 
Study Total Regressed Rate (%) 95% CI Regression rates, 95% CIa
Simple hyperplasia    
Oral Progestogens
Bese (2006) 19 19 100 64 – 157
Buttini (2009) 9 8 89 44 – 178
Clark (2006) 15 10 67 36 – 124
Guven (2001) 16 14 88 52 – 148
Jarvela (2005) 16 10 63 34 – 116
Milam (2008) 2 2 100 25 – 400
Rattanachaiyanont (2005) 116 108 93 77 – 112
Wang (2003) 5 4 80 30 – 213
Yener (1997) 15 12 80 45 – 141
Subtotal (95% CI) 213 89 77 – 102
Test for heterogeneity: p=0.948
LNG-IUS
Clark (2006) 3 3 100 32 – 310
Wildemeersch (2007) 12 12 100 57 – 176
Buttini (2009) 15 13 87 50 – 149
Varma (2008) 16 15 94 57 – 156
Vereide (2006) 11 11 100 55 – 181
Haimovich (2008) 15 15 100 60 – 166
Subtotal (95% CI) 72 96 76 – 122
Test for heterogeneity: p=0.999
P=0.41 for comparison between oral progestogens and LNG-IUSb 0%    50%      100%
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Complex hyperplasia
Oral Progestogens
Buttini (2009) 1 1 100 14 – 710
Clark (2006) 38 21 55 36 – 85
Guven (2001) 5 4 80 30 – 213
Horn (2004) 208 128 62 52 – 73
Jarvela (2005) 1 1 100 14 – 710
Milam (2008) 11 6 55 25 – 121
Rattanachaiyanont (2005) 18 16 89 54 – 145
Reed (2009) 95 68 72 56 – 91
Wang (2003) 12 9 75 39 – 144
Subtotal (95% CI) 389 66 58 – 74
Test for heterogeneity: p=0.856
LNG-IUS
Buttini (2009) 3 3 100 32 – 310
Clark (2006) 14 9 64 33 – 124
Varma (2008) 80 73 91 73 – 115
Vereide (2006) 5 5 100 42 – 240
Subtotal (95% CI) 102 92 65 – 109
Test for heterogeneity: p=0.776
P=0.001 for comparison between oral progestogens and LNG-IUSb 0%               50%                 100%
Atypical Hyperplasia
Oral Progestogens
Clark (2006) 5 0 10 1 – 160
Guven (2001) 3 2 67 17 – 267
Horn (2004) 7 0 7 0 – 114
Jobo (2001) 20 15 75 45 – 124
Kaku (2001) 18 11 61 34 – 110
Milam (2008) 1 0 50 3 – 799
Minaguchi (2007) 12 8 67 33 – 133
Randall (1997) 17 13 76 44 – 132
Reed (2009) 52 38 73 53 – 100
Signorelli (2009) 10 1 10 1 – 71
Wang (2003) 9 5 56 23 – 133
Wheeler (2007) 13 10 77 41 – 143
Witkiewicz (2010) 5 1 20 3 – 142
Yu (2009) 17 14 82 49 – 139
Subtotal (95% CI) 189 69 58 – 83
Test for heterogeneity: p=0.604
LNG-IUS
Clark (2006) 1 0 50 3 – 799
Buttini (2009) 1 1 100 14 – 710
Wheeler (2007) 5 5 100 42 – 240
Varma (2008) 9 6 67 30 – 148
Vereide (2006) 5 5 100 42 – 240
Tjalma (2004) 7 7 100 48 – 210
Wildemeersch (2007) 8 8 100 50 – 200
Subtotal (95% CI) 36 90 62 – 130
Test for heterogeneity: p=0.986
P=0.03 for comparison between oral progestogens and LNG-IUSb 0%                50%                100%
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Discussion 
This review,  which included 1001 women with EH, showed that complete regression of EH 
was achieved in a lower proportion of women treated with oral progestogens compared to 
women treated with LNG-IUS for complex (66% vs 92%) and atypical hyperplasia (69% vs 
90%).  There was no significant difference found between the two treatments for simple 
hyperplasia (89% vs 96%). 
 
Our study provides an overview of the efficacy of oral progestogens and LNG-IUS for the 
treatment of EH and summarises the current evidence.  It has major clinical relevance to the 
understanding and treatment of EH.  We meta-analysed the disease regression rates for both 
interventions separately for each type of EH.  This reduced potential heterogeneity between 
the studies and enhanced the clinical applicability of our findings.  We also assessed the 
heterogeneity both graphically using forest plots and statistically.  We contacted authors of 
the primary studies for clarification of relevant information.  We used a validated tool 
(MINORS) to rate the quality of the included studies.  
 
However, the strength of these findings is limited by the dearth of primary literature, 
unreliability of the data due to small numbers and the risk of bias in most of the studies due 
to their poor quality.  Furthermore, the interpretation of these findings should also take into 
account publication bias, which is likely to result in preferential reporting of cases with good 
outcomes, leading to possible overestimation of effect.  It is plausible that different types and 
doses of oral progestogens may have a differential effect on disease regression rates, but the 
large variation in type, dose and regimens of oral progestogens used, prevented us from 
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performing subgroup analyses to explore the differences in efficacy  However, there is no 
consistent evidence to suggest such a differential effect from the studies included in our 
review, as well as a large study by Reed et al
30
 which found that there are no differences in 
EH regression rates between the various oral progestogens 
 
We believe that the difference of disease regression rates of oral progestogens and LNG-IUS 
for the treatment of EH found in our review may be explained by the mode of progestogen 
delivery.  The progestogen concentrations in the uterine mucosa when delivered through an 
intrauterine device, directly into the cavity are reported to exceed that of the oral treatment by 
several-fold.
33
  The intrauterine progestogen release is also associated with higher patient 
satisfaction and, therefore patients are more likely to continue the treatment.  As discussed 
before, this higher chance of patients continuing the LNG-IUS treatment resulting in higher 
compliance may also explain its better efficacy in treating EH compared to oral progestogens.  
The higher disease regression rate with LNG-IUS can reduce the number of hysterectomies 
performed for this condition and prevent progression to cancer. 
 
In conclusion, although this review of observational studies found a lower chance of disease 
regression of EH with oral progestogens compared to LNG-IUS, it should be acknowledged 
that observational studies are fraught with potential biases and confounders.  Our systematic 
examination of the published literature confirms the scarcity of high-quality evidence to 
reliably inform clinical practice in this area.  Although the differences between oral 
progestogens and LNG-IUS may be seen as significant, these data should be interpreted with 
caution.  This is because the studies are of observational design with mostly indirect 
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comparisons between these two methods and small numbers of included women, especially 
for women with ACH.  As a result, the findings may be unreliable and in the absence of 
randomised studies with at least five years follow-up, (this review only had two studies with 
over five years follow up data) the efficacy of oral progestogens and LNG-IUS remains in 
doubt.  This  review may aid the design of an adequately powered, controlled study to assess 
the short- and long-term effects of these interventions.   
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Chapter 3: Regression, relapse, and live birth rates with fertility-
sparing therapy for EC and ACH: a systematic review and meta-
analysis. 
Abstract 
Objective  
To evaluate the regression, relapse and live birth rates of early-stage EC and ACH with 
fertility-sparing treatment. 
Methods 
This study was a meta-analysis of proportions from observational studies with random effects 
model and meta-regression to explore for heterogeneity.  
Results  
Thirty-four observational studies, evaluating the regression, relapse and live birth rates of 
early-stage EC (408 women) and ACH (151 women) with fertility-sparing treatment.  
Fertility-sparing treatment for EC achieved a pooled regression rate of 76.2%, a relapse rate 
of 40.6% and a live birth rate of 28%.  For ACH the pooled regression rate was 85.6%, a 
relapse rate of 26% and a live birth rate of 26.3%. Twenty women were diagnosed with 
ovarian cancer (concurrent or metastatic) during follow-up (3.6%) and 10 progressed to 
higher than stage I EC (1.9%) from which two women died.   
Conclusion  
Fertility-sparing treatment of EC and ACH is feasible and selected women can satisfy their 
reproductive wishes.  
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Introduction 
In 2007, 7,536 women in the UK were diagnosed with EC and 239 of these women were less 
than 45 years old (3.2%).
2
  Often, these women have strong fertility desires as anovulatory 
infertility is strongly associated with the development of EC and ACH.
65
  It is known that 
these women usually are usually diagnosed with early clinical stage well-differentiated EC, 
which carries a good prognosis.  Traditionally, it is recommended that these women undergo 
a staging abdominal hysterectomy.  However, multiple studies suggest that in selected 
women with early clinical stage disease this can be managed with fertility-sparing hormonal 
therapy.  The use of progestogens can induce endometrial regression and prevent progression 
of the disease.  Oral progestogens are used to treat EC and ACH but, more recently, the 
LNG-IUS has also been used successfully to treat ACH.
31
  Yet, there is significant 
uncertainty about the efficacy of these therapies from observational studies with small sample 
sizes, which makes difficult to counsel the women accordingly.  To ascertain the efficacy of 
these therapies, we conducted a systematic review of observational studies evaluating the 
regression, relapse and live birth rates for the treatment of EC and ACH and performed a 
meta-analysis of their treatment effects.  
 
Methods 
Identification of literature 
The population of interest in this systematic review was women with early clinical stage 
(FIGO stage I) EC or ACH, the intervention was fertility-sparing therapies and the outcome 
was evidence of disease regression, relapse and live births.  The following electronic 
databases were searched: MEDLINE (1950 to September 2011), EMBASE (1980 to 
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September 2011), Cochrane Central Register of Controlled Trials and Web of Science 
conference proceedings (ISI Proceedings, 1990 to September 2011).  A combination of 
Medical Subject Headings (MeSH) and text words were used to generate two subsets of 
citations, one including studies of EC (“endometr* cancer*”, “malignant endometr*”) or EH 
(“endometr* hyperplas*”, “premalignant endometr*”, “precancer* endometr*”) and the other 
including studies of fertility-sparing therapies such as progestogens and intrauterine devices 
or systems (“intrauterine devices medicated”, “Levonorgestrel”, “mirena”, “intrauterine 
progest*”, “LNG-IU*”, “progest*”, “gestag*”, “fertility-sparing therapy”, “conservative 
therapy”, “hormone* therapy”).  These subsets were combined with “AND” and limited to 
“Humans and Female” to generate a subset of citations.  The reference lists of all known 
primary and review articles were examined to identify cited articles not captured by 
electronic searches.  Language or geographical restrictions were not applied during search or 
selection.  
 
Study selection and data extraction 
Studies were selected if the participants were women diagnosed histologically with early 
clinical stage EC or ACH, the intervention was fertility-sparing therapy and the outcomes 
were histological disease regression, relapse or live birth rates.  Case reports or series with 
less than five cases were excluded.  Studies classifying women with EH in other than the 
WHO classification
7
 were also excluded.  
 
Studies were selected in a two-stage process.  First, the titles and abstracts from the electronic 
searches were scrutinised by two reviewers independently and full manuscripts of all 
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citations that met the predefined selection criteria were obtained.  Secondly, final inclusion or 
exclusion decisions were made on examination of the full manuscripts.  In cases of 
duplicates, the most recent or the most complete publication was used.  Any disagreements 
about inclusion were resolved by consensus or arbitration by a third reviewer.  Two 
reviewers completed the quality assessment.  The MINORS tool, which assesses the quality 
of the included studies, was implemented.
41 
  From each study, outcome data were extracted 
in 2x2 tables by the two reviewers.   
 
Disease regression was defined as lack of residual EC or CH during follow-up endometrial 
sampling.  Disease relapse was defined EC or CH diagnosis during follow-up endometrial 
sampling following an endometrial sample that showed disease regression.  Live births was 
defined as the birth of healthy infants during the follow-up period and its rate was calculated 
as the number of women who had a birth of healthy infants divided by the number of total of 
women undergoing fertility-sparing therapy.  We also counted the number of women that 
were diagnosed with concurrent or metastatic ovarian cancer or upgraded disease to higher 
than stage I and deaths from this disease during follow-up.  
 
Statistical analysis 
Regression, relapse and live birth rates were extracted from each study and we computed the 
log of the ratio and its corresponding standard error for each study.  We performed the meta-
analysis using inverse-variance weighting to calculate the random effects summary 
estimates.
66
  We obtained an estimate of the between-study variance with a random-effects 
meta-analysis. The square root of this number is the estimated standard deviation of 
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underlying effects across studies.  Since we had relative measures of effect, the confidence 
intervals were centred on the natural logarithm of the pooled estimate, and the limits 
exponentiated to obtain an interval on the ratio scale.
67
  Forest plots were created for each 
outcome, showing individual study proportions with confidence intervals (CIs) and the 
overall DerSimmonian-Laird pooled estimate.
43
  Heterogeneity of the treatment effects was 
assessed graphically with forest plots and statistically analysed using the χ2 test.44  
Exploration of the causes of heterogeneity for the live birth rate was planned according to the 
reproductive method and it was assessed with the aid of meta-regression.
45
  Statistical 
analyses were performed using Stata 8.0 (Stata Corp, TX, USA). 
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Figure 4 Study selection process for systematic review of fertility-sparing treatment for EC and ACH 
 
Results 
Selection, characteristics and quality of the primary studies 
The electronic search strategy yielded 9,516 citations and we retrieved further 10 citations 
from our manual checking of reference lists of all primary articles.  Of these, 9,477 citations 
were excluded as they did not fulfil the selection criteria.  Examination of the full-text of the 
remaining 54 manuscripts found a total of 34 primary studies,
 68-94 
including 559 women of 
which 408 were diagnosed with EC and 151 with ACH, for inclusion in this review (Figure 
4).  The main characteristics of the 34 studies and the study methodological index are  
presented in Table 2 and Figure 5.   
 
 
Total number of citations retrieved from electronic searches and from examination of 
reference lists of primary and review articles: n =9,526  (Medline=4,496; 
Embase=5,020; manual checking of reference lists=10)
Citations excluded after screening title and/or abstracts: n =9,477 
Full manuscripts retrieved for detailed evaluation: n =54 
Primary articles fulfilling inclusion criteria for systematic review: n=34
Articles excluded after review of full text with reasons.
Case reports or cases less than five n=8
Lack of original data i.e. reviews/letters n=4
Inappropriate population n=4
Data not extractable n=2
Duplicate publication n=2
Total excluded n=20
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The primary studies included women with well-differentiated EC with 386 women being 
classified as G1 and 22 women with moderate or poor differentiation (G2 or G3).  In 24 
studies the women enrolled underwent diagnostic imaging to rule out myometrial invasion or 
distant disease.  In 11 of these 24 studies, serum CA-125 marker was measured to also rule 
out concurrent ovarian malignancy.  The quality of the studies on the MINORS checklist is 
shown in Figure 5.  More in detail, half of the studies were prospective cohorts (17/34) 
including consecutive patients (31/34) with adequate definition of outcomes (30/34).  No 
studies had a blinded assessment of the outcomes or performed a prospective calculation of 
the study size.  We defined appropriate follow-up to be at least five years and we found that 
only in 6/34 studies follow-up was more than five years. 
Figure 5 Quality assessment of the studies for the systematic review of fertility-sparing treatment for EC and ACH 
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Figure 6 Forest plot of metaanalysis of regression rates for fertility-sparing treatment of EC 
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Figure 7 Forest plot of metaanalysis of relapse rates for fertility-sparing treatment of EC 
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Figure 8 Forest plot of metaanalysis of live birth rates for fertility-sparing treatment of EC 
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Figure 9 Forest plot of metaanalysis of regression rates for fertility-sparing treatment of ACH 
 
Figure 10 Forest plot of metaanalysis of relapse rates for fertility-sparing treatment of ACH 
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Figure 11 Forest plot of metaanalysis of live birth rates for fertility-sparing treatment of ACH 
 
 
 
 
 
Table 2 Characteristics of the studies. 
Author-
Year 
Recruitment 
Study population 
Intervention or study groups 
Outcomes 
(rates) 
Follow-
up 
(median, 
Range in 
months) 
Women treated 
Investigations prior to 
treatment to rule out 
invasion 
Imaging 
Tumour 
markers 
Bokhman-
1985 (n=19)
 
Prospective G1 (n=11) or G2 
(n=8) EC  
No No Hydroxyprogesterone 500mg/day for 
at least 3 months 
Regression n/a 
Cade-2010 
(n=16)
 
Retrospective   G1 EC   MRI No MPA only (n=4) 60-400mg/day, 
MPA 200-400mg/day with LNG-IUS 
(n=9) or LNG-IUS (n=3) 
Regression, 
relapse and 
live birth 
27, 3-134 
Duska-2001 
(n=12)
 
Retrospective   G1 EC  No No Progestogens at various doses Regression, 
relapse, and 
live birth  
82, 6-358 
Eftekhar-2009 
(n=21)
 
Prospective   G1 EC  MRI, CT 
and USD 
CA125 MA 160 mg/day  Regression, 
relapse, and 
live birth  
 39, 5-
108 
Elizur-2007 
(n=8)
 
Prospective 
cohort  study 
G1 EC   MRI CA125 MA 160 mg/day (n=6), MPA 
200mg/day (n=1) or 600mg/day 
(n=1) for at least 3 months 
Regression, 
relapse and 
live birth   
51, 38-75 
Gotlieb-2003 
(n=13)
 
Retrospective   G1 (n=11) or 
G2-3 (n=2) EC 
MRI, CT CA125 MA 160 mg/day (n=8), 
Hydroxyprogesterone 8-12g/day 
(n=2), NET 5mg/day (n=1), MPA 
200-600mg/day (n=2) for at least 3 
Regression, 
relapse and 
live birth   
 35, 10-
146 
Study
Han (2009)
Subtotal (95% CI)
Test for heterogeneity: Q=4.480 on 9 degrees of freedom (p=0.877)
3
126
1
31
33 [5, 237]
26.3 [18.5, 37.4]
100%
Live birth rates (Random), 95% CILive births
Total of 
patients Rates [95% CI]
Jadoul (2003)
Kaku (2001)
2
18
1
4
50 [7, 355]
22 [8, 59]
Minaguchi (2007)
Minig (2010)
12
20
2
6
17 [4, 67]
30 [13, 67]
Randall (1999)
Signorelli (2009)
Ushijima (2007)
19
10
17
3
5
4
16 [5, 49]
50 [21, 120]
24 [9, 63]
Yu (2009) 173 18[6, 55]
90%80%70%60%50%40%30%20%10%0%
Le Digabel (2006) 82 25 [6, 100]
51 
 
months 
Hahn-2009 
(n=35)
 
Retrospective   G1 (n=31) or G1 
and focal G2 
(n=4) EC 
MRI, CT 
and USD 
CA125 MA 160 mg/day (n=8) or MPA 250-
1500mg/day (n=20) or in 
combination (n=7) 
Regression, 
relapse and 
live birth   
23, 2-72 
Han-2009 
(n=10)
 
Retrospective   G1 (n=5) or G2 
(n=2) EC or 
ACH (n=3)  
MRI and 
USD 
CA125 MA 80-160 mg/day (n=7), MPA 20-
1000mg/day (n=3) for at least 3 
months 
Regression, 
relapse and 
live birth   
 31.5, 10-
133 
Imai-2001 
(n=14)
 
Retrospective   stage I G1 (n=5) 
or G2 (n=1) and 
stage II G1 
(n=7) or G2 
(n=1) EC 
No No MPA 400-800mg/day Regression, 
relapse and 
live birth   
12.9, 7-
46 
Jadoul-2003 
(n=7)
 
Retrospective   G1 EC  (n=5) or 
ACH (n=2)  
No No Endometrial resection followed by 
GnRH-analogues 
Regression, 
relapse and 
live birth   
40, 26-40 
Kaku-2001 
(n=30)
 
Retrospective   G1 (n=10) or G2 
(n=2)  EC or 
ACH (n=18) 
MRI, CT 
and USD 
No  MPA 200-800mg/day for EC (n=12) 
and 100-600mg/day for ACH (n=18) 
for 3-6 months 
Regression, 
relapse and 
live birth   
38.7, 17-
84 
Kim-2000 
(n=7)
 
Retrospective    G1 EC No No MA 160 mg/day for at least 3 months Regression, 
relapse and 
live birth   
11.7, 3-
30 
Laurelli-2011 
(n=14)
 
Prospective   Stage IA G1 EC  MRI and 
USD 
No Hysteroscopic resection of the 
tumour followed by MA 160 mg/day 
for 6 months (n=6) or LNG-IUS (52 
mg/day) (n=8) for 12 months  
Regression, 
relapse and 
live birth   
n/a 
Le-Digabel-
2006 (n=13)
 
Retrospective   Stage IA G1-2 
(n=3) or Stage 
IB G2-3 (n=2)  
EC or ACH 
(n=8)  
No No Progestogens at various doses (n=6) 
or LHRH-analogues (n=3) or 
combination of the two (n=2) or 
endometrial curettage (n=2) 
Regression, 
relapse and 
live birth   
50.5, 32-
77 
Lee-2010 
(n=12)
 
Prospective   ACH (n=1), 
other 
hyperplasia 
(n=11) 
No No Progesterone-releasing IUD system 
(20µg/day) 
Regression 
and  relapse  
50.5, 21-
82 
Li-2008 (n=5)
 
Prospective   ACH (n=3), 
other 
hyperplasia 
(n=2) 
No No Letrozole 2.5mg/day for 3 months Regression, 
relapse and 
live birth   
 40.7, 2-
109  
Mao-2010 
(n=6)
 
Prospective   G1 EC  MRI, CT 
and USD 
CA125 MA 160 mg/day (n=2), MPA 250-
500mg/day (n=4) 
Regression, 
relapse and 
live birth   
 29, 4-
102  
Mazzon-2010 
(n=6)
 
Prospective   Stage IA G1 EC MRI CA125 Hysteroscopic resection of the 
tumour followed by MA 160 mg/day 
for 6 months 
Regression, 
relapse and 
live birth   
43, 3-75  
Minaguchi-
2007
 
(n=31)
 
Prospective   Stage IaG1 EC 
(n=19) or ACH 
(n=12) 
MRI, CT 
and USD 
No MPA 2.5mg-600mg/day, mostly 400-
600mg/day for 6 months 
Regression, 
relapse and 
live birth   
 55.8, 24-
138  
Minig-2010
 
(n=34)
 
Prospective   Stage IaG1 EC 
(n=14) or ACH 
(n=20) 
MRI and 
USD 
CA125 LNG-IUS (20µg/day) for 12 months 
and GnRH analogue (3.75mg depot) 
for 6 months  
Regression, 
relapse and 
live birth   
 43.5, 13-
127  
Montz-2002
 
(n=12)
 
Prospective   Stage IaG1 EC 
(n=12) 
MRI and 
USD 
No Progesterone-releasing IUD 
(65µg/day)  
Regression 
and relapse 
47.3, 18-
135  
Niwa-2005 
(n=12)
 
Prospective   Stage IaG1 EC MRI and 
USD 
CA125 MPA 400mg-600mg/day for at least 
6 months 
Regression, 
relapse and 
 60.2, 8-
412 
52 
 
live birth   
Ota-2005 
(n=12)
 
Retrospective   Stage IaG1 EC MRI, CT 
and USD 
No MPA 600mg/day  Regression, 
relapse and 
live birth   
40, 9-79 
Park-2011 
(n=14)
 
Retrospective   Stage IaG1 EC MRI No MPA 250-500mg/day (n=10) or 
Provera 30mg/day (n=2) or MA 16-
240mg/day (n=2) 
Regression, 
relapse and 
live birth   
 98, 35-
176  
Perri-2011 
(n=27)
 
Retrospective   Stage I EC  MRI, CT 
and USD 
CA125 MA 160-320 mg/day (n=21), NET 5 
mg/day (n=1), Hydroxyprogesterone 
2-3 g/week (n=2), and MPA 100-600 
mg/day (n=3)  
 
Regression, 
relapse and 
live birth   
 47.9, 25-
73  
Randall-1997
 
(n=33)
 
Retrospective   G1 EC (n=14) or 
ACH (n=19)   
No No MPA 10-30mg/day or MA 40-
160mg/day (n=29), ovulation 
induction (n=2), Bromocriptine 
(n=1), oral contraceptive (n=1) for 3-
12 months 
Regression, 
relapse and 
live birth   
 69, 25-
113  
Signorelli-
2009
 
(n=21)
 
Prospective   Stage IaG1 EC 
(n=11) or ACH 
(n=10) 
MRI, CT 
and USD 
CA125, 
CA19.9 
Natural progesterone 200mg/day 
D14-25  
Regression, 
relapse and 
live birth   
 11, n/a 
Ushijima-
2007
 
(n=45)
 
Prospective   Stage IaG1 EC 
(n=28) or ACH 
(n=17)  
MRI CA125 MPA 600mg/day with low dose 
(81mg) aspirin 
Regression, 
relapse and 
live birth   
76.5, 21-
118  
Wang-2002
 
(n=9)
 
Prospective   Stage IaG1 EC MRI and 
USD 
CA125 MA 160 mg/day and tamoxifen 
30 mg/day for 6 months 
Regression, 
relapse and 
live birth   
39, 24-69  
Wheeler-2007 
(n=44)
 
Retrospective   G1 EC (n=26) or 
ACH (n=18)  
No No Oral progestogens (n=29) or 
progesterone-releasing IUD (n=15)  
Outcome: 
Regression 
and relapse  
48.8, 14-
132  
Yahata-2005
 
(n=8)
 
Prospective   Stage IaG1 EC MRI and 
USD 
No MPA 1800mg/day for at least 3 
months 
Regression, 
relapse and 
live birth   
34.6, 7-
114 
Yamazawa-
2007
 
(n=9)
 
Prospective   Stage IaG1 EC MRI and 
CT 
CA125 MPA 400mg/day for at least 6 
months 
Regression, 
relapse and 
live birth   
82, 6-358 
Yang-2005
 
(n=6)
 
Prospective   Stage IaG1 EC MRI, CT 
and USD 
No MA 160mg/day for at least 6 months Regression, 
relapse and 
live birth   
 39, 5-
108 
Yu-2009
 
(n=25)
 
Retrospective   Stage IaG1 EC 
(n=8) or ACH 
(n=17) 
MRI, CT 
and USD 
CA125 MPA 250-500mg/day for EC and 
100-500mg/day for ACH (n=22) or 
MA or Hydroxyprogesterone (n=3) 
Regression, 
relapse and 
live birth   
51, 38-75 
Abbreviations EC: endometrial cancer, ACH: atypical complex hyperplasia, LNG-IUS: Levonorgestrel-
releasing Intrauterine System, HRT: Hormone Replacement Therapy, IUD:
 
Intrauterine Device, MPA: 
Medroxyprogesterone acetate, MA: Megestrol acetate, NET: Norethisterone 
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Regression, relapse, and live birth rates of fertility-sparing treatment for EC 
Meta-analysis of the 32 studies (408 women) of women with EC managed with fertility-
sparing treatment found that 301 women regressed with a pooled regression rate of 76.2% 
(95% CI 68-85.3, Figure 6).  The p value for the χ2 test for heterogeneity was 0.976 
indicating insignificant variability in regression rates between the studies.  In 29 of these 
studies (267 women) women were followed up over time with the median ranging from 11 to 
76.5 months and the relapse rates were reported.  We found that 89 women after an initial 
regression of the EC they relapsed during follow-up which amounts to a pooled relapse rate 
of 40.6% (95% CI 33.1-49.8) without significant variability (p=0.566, Figure 7).  Meta-
analysis of the 26 studies reporting pregnancy outcomes showed that from 325 women 
undergoing fertility-sparing treatment for EC, 75 women achieved at least one live birth with 
a pooled live birth rate was 28% (95% CI 21.6-36.3) with minimal heterogeneity (p=0.197, 
Figure 8). 
 
Regression, relapse, and live birth rates of fertility-sparing treatment for ACH  
For ACH, meta-analysis of the 14 studies (151 women) found that 127 women regressed with 
a pooled regression rate of 85.6% (95% CI 72-100%, Figure 9).  The p value for the χ2 test 
for heterogeneity was 0.99 indicating no variability in regression rates between the studies.  
In 13 of these studies (126 women) women were followed up over time with the median 
ranging from 11 to 76.5 months and the relapse rates were reported.  We found that 27 
women after an initial regression of the ACH they relapsed during follow-up which amounts 
to a pooled relapse rate of 26% (95% CI 18-37.6) again without any observed variability 
(p=0.923, Figure 10).  For ACH, meta-analysis of the 10 studies reporting pregnancy 
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outcomes showed that from 126 women, 31 women achieved at least one live birth with a 
pooled live birth rate was 26.3% (95% CI 18.5-37.4%) with insignificant heterogeneity 
(p=0.877, Figure 11).   
 
Assisted reproduction versus spontaneous pregnancy 
From the 451 women that had fertility-sparing treatment for EC or ACH, 142 had assisted 
reproduction treatment to achieve pregnancy and 56 of them achieved at least one live birth.  
This amounts to a 39.4% live birth rate.  The remaining 309 women are presumed to have 
tried to spontaneously conceive and 46 women achieved at least one live birth with a rate of 
14.9%.  This difference between assisted reproduction and spontaneous conception in 
achieving a live birth was statistically significant (p=0.001) in meta-regression analysis.   
 
Safety of fertility-sparing treatment 
There were 20 diagnoses of ovarian malignancy during follow-up (20/559, 3.6%) and it was 
not always clear from the primary studies whether they represented concurrent ovarian 
malignancies or metastatic ovarian involvement from the endometrial primary neoplasm.  
The type of ovarian cancer and staging was poorly reported, but 10 women were diagnosed 
with endometrioid adenocarcinoma of the ovary (10/559, 1.8%).  The pre-operative imaging 
or tumour marker investigations did not appear to reduce this incidence as in 11 studies that 
carried out these investigations, ovarian malignancy was diagnosed during follow-up in 8 
women (8/200, 4%) comparing to 13 studies where only imaging was used and there were 5 
ovarian malignancies diagnosed (5/217, 2.3%) and in 10 studies with no such investigations 
there were 7 ovarian malignancies diagnosed (7/142, 4.9%).  There were also 10 women 
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(10/559, 1.8%) diagnosed with stage II EC or higher after failing treatment.  In one case there 
was a distal lymphatic metastasis involving the obturator lymphatic node.
34 
 There were two 
deaths from fertility-sparing treatment for EC (2/559, 0.36%), one from a diagnosis of a 
synchronous endometrial, ovarian and peritoneal malignancy
83
 and one from an ovarian 
malignancy on a patient who on recurrence only underwent total hysterectomy without 
salpingo-oophorectomy as did not wish to have menopausal symptoms.
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Discussion 
This meta-analysis, which included 408 women with EC and 151 with ACH, found that the 
regression rates with fertility-sparing treatment are very encouraging (76% for EC and 86% 
for ACH).  An also encouraging proportion of women choosing this treatment for preserving 
their fertility managed to achieve live births (28% of women with EC and 26% of women 
with ACH).  Women choosing assisted reproductive treatment had significantly better results 
regardless of the initial diagnosis.  However, the relapse rates during follow-up are worrying 
(41% for EC and 26% for ACH).  The incidence of ovarian malignancies in 20 women 
during follow-up is also worrying (3.6%) and the pre-operative imaging or CA-125 testing, 
even though essential, did not lower this incidence.  The upgrade of disease in further 10 
cases along with distant metastases in 2 of these cases also represents a considerable risk of 
this treatment.  There were two deaths reported.  
 
Our study provides an overview of the efficacy of fertility-sparing treatment for early-stage 
EC and ACH and summarises the current evidence.  It has major clinical relevance for young 
women that wish to preserve their fertility.  We reduced potential publication bias by 
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excluding case-reports and cases-series of less than five cases.  We contacted authors of the 
primary studies for clarification of relevant information.  Finally, we calculated the events of 
disease upgrade during follow-up and adverse outcomes with fertility-sparing therapy.  Other 
systematic reviews produced a mean of the observed rates which does not take into account 
the specific weight of the studies and their variability.
93
  The use of a random effects model 
to combine the data across studies helps to control for differences between the studies.  
However, since the studies included in this meta-analysis are all observational studies there is  
bias that is introduced and the strength of the findings in this review including 34 studies is 
limited by the dearth of primary literature.  The unstable study estimates and wide confidence 
intervals due to small numbers along with the risk of bias in most of the studies due to their 
study design and short-term follow-up reduce the strength of our inferences.  Specifically, the 
relapse and live birth rates may prove to be higher if women were followed up for at least 
five years following their diagnosis.
95
  It is reported that relapse may be more likely for obese 
women,
95
 but the primary studies included in our analysis did not report the treatment effects 
taking into account obesity.  It is plausible also that different types and doses of hormones 
may have a differential effect on disease regression rates, but the large variation in type, dose 
and regimens of oral progestogens used, prevented us from performing subgroup analyses to 
explore the differences in efficacy.  In addition, there were only two studies that used the 
LNG-IUS and the majority of the evidence is from oral progestogens hence, our findings may 
not be generalisable to women treated with LNG-IUS and further research is encouraged. The 
variability across the studies was found to be statistically low, but this test may not be a 
reliable evaluation of the clinical variation in the studies because of small sample sizes.   
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We believe that even though the diagnosis of EC or ACH in women that wish to preserve 
fertility is uncommon, it is a management dilemma for clinicians. Fertility-sparing treatment 
does represent an option for these women with encouraging results, but also important risks.  
Women wishing to pursue this treatment would need to be counselled thoroughly about the 
benefits and the potential risks and informed of paucity of good quality evidence to guide the 
clinical decision-making.  From the available data we can make suggestions for clinical 
practice and management, but caution is advised as the evidence backing these suggestions is 
poor.  We suggest that pre-treatment investigations, should aim to rule out myometrial 
invasion and concurrent ovarian cancer, even though there are no reliable tests for this 
purpose.  These should include imaging, such as transvaginal ultrasound and CT or MRI, 
along with tumour serum markers, but the limitations of these investigations should be taken 
into account.  In the primary studies, these tests did not lower the incidence of ovarian cancer 
diagnosis during follow-up, but as this is a rare outcome this review may be underpowered to 
draw strong conclusions on this and we also cannot rule out a different case mix across the 
studies.  We should also point out that there is uncertainty about the treatment regimen and 
the follow-up, which is reflected in our studies where various therapies were employed.  The 
studies included in this review suggest that when a diagnosis of EC or ACH has been made 
this should be treated for at least three and up to 12 months.  A repeat biopsy should confirm 
regression before women attempt to get pregnant.  Considering the high relapse rate of the 
disease once the treatment is stopped and the potential of disease progression, it is sensible to 
recommend to these women to undergo staging hysterectomy with bilateral salpingo-
oophorectomy.  This should be recommended to women once their family is complete or if 
fertility-sparing treatment fails, either because of failure in regressing their disease or relapse.  
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If regression is achieved we would also recommend that these women are encouraged to 
undertake assisted reproduction treatment in order to maximise their chances of a live birth 
and minimize time before a hysterectomy, which could prevent them from relapse.  
Immediate assisted reproduction treatment avoids prolonged unopposed oestrogen 
stimulation, which could cause women to relapse.  Finally, clinicians should consider 
following women that decline hysterectomy for at least five years or even longer and not to 
underestimate the risk of relapse. 
  
In conclusion, this review of observational studies found a high chance of disease regression 
and encouraging live birth rates of early-stage EC and ACH with fertility-sparing treatment 
followed by assisted reproduction.  The risk of disease relapse and upgrade during follow up 
is considerable.  Our systematic examination of the published literature confirms that there is 
only limited quality observational evidence to inform clinical practice and results should be 
interpreted with caution.  Our review may aid the design of a  cohort study to assess the 
short- and long-term effects of the fertility-sparing treatment.   
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Chapter 4: Current management of endometrial hyperplasia—a 
survey of United Kingdom consultant gynaecologists.  
Abstract 
Objective  
To determine current clinical practice for the management of EH.  
Methods  
We carried out a web-based survey of all UK consultant gynaecologists, from the Royal 
College of Obstetricians and Gynaecologists (RCOG) database, to evaluate the current 
practice and to enquire whether a trial between oral progestogens and LNG-IUS for EH is 
required.  
Results  
We sent 1090 email invitations and 411 (37.7%) responded to this survey.  In total, 338 
consultant gynaecologists, who manage patients with EH, responded to all items of the 
survey. The oral progestogens (33.2%) and the LNG-IUS (52.1%) were the most popular 
choices for managing CH.  The majority of the gynaecologists would explore two 
conservative choices before embarking into performing a hysterectomy for this condition 
(130, 52.6%).  However, for ACH, the majority of the gynaecologists would perform a 
hysterectomy (273, 83.2%) and would only consider LNG-IUS or oral progestogens as a 
second or third option.  Two hundred forty-four (72.2%) responded that an RCT for oral 
progestogens versus LNG-IUS for the management of EH is required. There were 171 
(50.6%) gynaecologists that would be willing to randomise in such an RCT.  
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Conclusion Our survey shows that CH is managed conservatively in UK, with oral 
progestogens or LNG-IUS, and ACH is managed with hysterectomy. An RCT, between oral 
progestogens and LNG-IUS for EH, is required to identify the optimum therapy.  
 
Introduction 
Non-surgical therapeutic strategies in EH aim to induce disease regression and prevent 
progression to cancer. These strategies, if successful could reduce the number of 
hysterectomies performed for this condition and hence reduce morbidity and healthcare costs. 
Currently, there are no professional body guidelines for the management of EH.  The use of 
progestogens, which antagonise the oestrogen effect on the endometrium, can induce 
endometrial regression and prevent progression to cancer
4
 and the LNG-IUS developed 
primarily as a contraceptive device, has also been used successfully to treat EH.
31
  This 
system has been proven to achieve higher regression rates than the oral progestogens in our 
systematic review and meta-analysis of observational studies.
95
  However, this systematic 
examination of the published literature confirms that the quality of the published data was 
poor with short term follow up and small sample sizes.
95
  We conducted a RCOG-based 
survey to identify the current practice for the treatment of EH and whether there is need for 
further research in terms of a randomised controlled trial.  
 
Methods 
The survey population consisted of all 1268 consultants in UK holding membership of the 
Royal College of Obstetricians and Gynaecologists (RCOG).  They were identified through 
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the RCOG database that includes consultants that have consented for the College to share 
their contact details with third parties.  The database contained the contact details for 1268 
consultants.  Of these, 178 email addresses were not valid at the time of the survey.  As a 
result, our population for this survey consisted of 1090 consultants receiving an email 
invitation.  The email invitation contained a link to a website access to the survey.  The 
survey questionnaire was designed to explore the current management of EH.  It contained 
separate questions for CH and ACH.  The gynaecologists could rank three different choices 
out of a list which contained observation only, medical management (i.e. LNG-IUS, oral 
progestogens) or surgical management (i.e. hysterectomy) or observation only.  The 
gynaecologists were made aware of the current observational evidence quoting the regression 
rates with oral progestogens (about 70%) and LNG-IUS (about 90%)
96
 and on this basis, they 
were asked whether they believed further research in the form of a randomised controlled 
trial was necessary.  We also enquired about interest for recruiting in such a trial and we 
invited comments about any serious concerns.  The questionnaire also contained two filter 
questions.  There were used for selecting only gynaecologists that manage women with EH 
for completing this survey.  The questionnaire was piloted on 39 consultants for obtaining a 
user-friendly structured format.   
 
Results 
We sent 1090 email invitations and 411 (37.7%) responded to this survey (Table 3).  Table 4 
shows the preferred choice for managing complex EH.   
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Table 3 Responses to the survey on the current management of EH in the UK 
 
The oral progestogens (33.2%) and the LNG-IUS (52.1%) were the most popular choices for 
managing this condition.  The majority of the gynaecologists would explore two conservative 
choices before embarking into performing a hysterectomy (130, 52.6%).  However, for ACH, 
the majority of the gynaecologists would preferably perform a hysterectomy (273, 83.2%) 
and would only consider LNG-IUS or oral progestogens as a second or third option (Table 5).   
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Table 4 Current management of CH in the UK 
 
The main reason for the surgical intervention in these patients is the fear of progression or co-
existent EC.  From the 338 gynaecologists that we asked if further research is required, 244 
(72.2%) responded that an RCT for LNG-IUS versus oral progestogens for the management 
of EH is required, 81 (23.9%) thought that an RCT was not required and 13 (3.9%) did not 
respond to this question.  There were 171 (50.6%) gynaecologists that would be willing to 
randomise in such an RCT, 62 (18.3%) that would not randomise, 92 (27.2%) were not sure 
if they would participate and 13 (3.9%) did not respond to this question.  Gynaecologists 
were reluctant to randomise in such an RCT, either because they manage small numbers of 
patients with hyperplasia (14/62, 22.6%) and because they did not want or they preferred for 
gynaecology oncology colleagues to manage ACH patients (13/62, 21%).  Interestingly, only 
3 (4.8%) gynaecologists had a strong preference for a type of treatment and did not want to 
randomise to this study for this reason.   
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Table 5 Current management of ACH in the UK 
 
Discussion 
The vast majority of the gynaecologists in UK treat CH with LNG-IUS or oral progestogens.  
For ACH, the consensus is to perform hysterectomy and only if this is not possible, oral 
progestogens or LNG-IUS are used for this purpose. The reason for this intervention is the 
high probability of progression or co-existent EC.  More than three out of four gynaecologists 
in this survey believes more research is required for the management of EH and two out of 
three of those would be willing to randomise in an RCT comparing LNG-IUS versus oral 
progestogens for EH.  In our knowledge, this is the only published survey evaluating the 
management of EH.  There is much debate around what is the best way to treat this condition, 
but only low quality observational studies are available to inform the clinical practice.
95
  
These observational studies showed a higher regression rate of the condition with the LNG-
IUS compared to the oral progestogens (about 90% versus 70%).
95
  We made this 
information available to the gynaecologists we surveyed and, despite that, over three out of 
four of the gynaecologists believed further research was required.  However, gynaecologists 
often tailor their treatment according to age, comorbidities and fertility desire and many 
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commented in our survey that it influences their clinical decision-making.  The diagnostic 
method (endometrial suction biopsy or curettage) was very rarely mentioned to influence 
treatment choice.  Clinicians believe that a randomised controlled trial can overcome the 
pitfalls of the low methodological quality observational studies and help them decide if LNG-
IUS or oral progestogens are more effective in treating EH.  The response rate to this survey 
was low (37.7%).  This introduces selection bias and threatens the internal validity and 
precision of the results.
96
  The reason is that non- responders may have answered differently 
altering significantly the results of this survey.  However, we limited our survey only to 
consultants that manage this condition, which is almost exclusively of general gynaecological 
interest.  We expect that about 30–40% of the clinicians included in our invitation to 
complete the survey were obstetricians.  This survey may have been of low interest to them, 
therefore, explaining the poor response from this group.  A high number of specialist 
gynaecologists (i.e. assisted conception specialists or urogynaecologists) would also not be 
interested in this condition as they would rarely have to manage patients with EH.  The 
design of this study does not allow us to address potential response and recall bias, but we 
attempted to minimise this with specific and direct questions.  Specifically we believe that 
those clinicians routinely managing these patients on a current day to day basis were more 
likely to have participated to this survey.  Our data from this survey show a strong trend 
towards conservative management of CH, with LNG-IUS or oral progestogens, and a surgical 
management of ACH with hysterectomy.  It is unlikely that this trend is biased or that it 
would have changed with a higher response rate.  Even though the observational studies are 
favouring the LNG-IUS, the gynaecologists believe that further research, and specifically an 
RCT between the LNG-IUS and oral progestogens for EH, is required.  The high risk of EC 
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with the ACH makes the option of hysterectomy almost mandatory.  However, the majority 
of women are diagnosed with CH (>80%) and most of the clinicians would be willing to treat 
this with hormonal therapy.
29
  As shown in this survey, this is done in over 80% of the cases 
with LNG-IUS or oral progestogens.  Even though the observational studies are favouring the 
LNG-IUS, the clinicians believe that further research, and specifically an RCT between the 
LNG-IUS and oral progestogens for EH is required.  
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Chapter 5: LNG-IUS versus oral progestogen treatment for EH: A long-
term comparative cohort study. 
Abstract 
Objective  
Compare the regression rate of the LNG-IUS versus oral progestogens for the treatment of 
women with EH. 
Methods This was a comparative observational study with long term follow up in a tertiary 
care university hospital.  Three hundred forty four women with CH or ACH participated in 
the study.  Women were treated with LNG-IUS (n=250) or oral progestogens (n=94).  We 
evaluated the proportion of women that regressed or had hysterectomy after treatment with 
LNG-IUS compared to oral progestogens by logistic regression adjusting for confounding. 
Results  
Follow up rate was 95.3%.  The mean length of follow up in the two groups was 66.9 ± SD 
35.1 months for the LNG-IUS versus 87.2 ± SD 45.5 months for the oral progestogen group.  
Regression of hyperplasia was achieved in 94.8% (237/250) of patients with LNG-IUS 
compared to 84% (79/94) of patients treated with oral progestogens (OR=3.46, 95% CI 1.58–
7.19).  Hysterectomy rates were lower in the LNG-IUS group during follow up (22.1%, 
55/250 vs. 37.2%, 35/94, OR=0.48, 95% CI 0.29–0.8).  EC was diagnosed in 8 (33%) women 
that had hysterectomy (n=24) because of failure to regress to normal histology during follow 
up.  
Conclusion  
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LNG-IUS achieved higher regression rate in treating EH with lower hysterectomy rates than 
the oral progestogens. Failure to achieve regression of EH carries a high risk of underlying 
EC. 
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Introduction 
EH is the precursor of EC and without intervention, the risk of progression to carcinoma is 
significant.
4
  ACH has also been associated with up to 43% rate of concomitant carcinoma in 
women undergoing hysterectomy.
11
  As the rate of progression to carcinoma for SH is low 
and often regresses spontaneously, the treatment interventions are therefore aimed to treat 
mostly CH and ACH patients.
4  
The treatment modality selected is dependent upon the 
woman‟s desire to retain fertility, medical fitness for surgical intervention and histological 
diagnosis.  In women in whom cytological atypia is present, the recommended and 
undisputed definitive treatment remains hysterectomy.  Traditionally hysterectomy was 
recommended for CH cases but it is not possible for all given its potential risks, especially for 
older or obese patients and those with significant co-morbidities.  Medical management of 
EH is therefore advocated in such cases.  In our national survey we found that more than 85% 
of gynaecologists treat CH with LNG-IUS or oral progestogens.
96
  Oral progestogens have 
been used in various dosages and regimens to treat hyperplasia since 1959, with the 
commonest treatment time interval of six months and then stopping treatment after regression 
is confirmed.
95;97
  However, our meta-analysis already showed that oral treatment is inferior 
in treating EH compared to LNG-IUS.
95
  This meta-analysis also highlighted the scarcity of 
high quality comparative studies with long term follow up for assessing the efficacy of these 
two treatment options and called for further evidence to help decide which one is the 
treatment of choice.
95
  Our objective was to conduct a large comparative cohort study with a 
long term follow up comparing the regression and hysterectomy rates of treatment with 
LNG-IUS and oral progestogens in patients diagnosed with CH or ACH. 
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Methods 
This was a comparative cohort study.  We included all women diagnosed with CH or ACH 
that underwent treatment with LNG-IUS or oral progestogens in a tertiary referral Hospital in 
Birmingham, UK.  For women treated with LNG-IUS we obtained demographic and follow 
up data at the time of the diagnosis from August 1998.  All women treated after August 2008 
were recruited prospectively in our study with written consent (Appendix 1 and 2).  Women 
with CH and ACH treated with oral progestogens from August 1998 until August 2008 were 
invited for long term follow up in our clinic and continue to be followed up ever since.  
These women were identified through a central electronic histopathology database, which 
includes all patients diagnosed with EH in our hospital for the study with no missing patients.  
The histopathological diagnoses were undertaken by two experienced gynaecological 
pathologists working independently; referral to the other pathologist for a second opinion was 
made in cases where there was diagnostic doubt, and a mutual consensus was then achieved.  
Women were reviewed in our gynecology outpatient clinic following diagnosis and were 
offered LNG-IUS (Mirena
®
, Bayer Healthcare Inc.), oral progestogens or hysterectomy as 
part of our routine clinical practice.  Women diagnosed with ACH were counselled and 
offered a hysterectomy.  Women who declined surgery or who were medically unfit to 
undergo surgery were offered LNG-IUS or oral progestogens.  Women underwent regular 
outpatient clinic review and endometrial histological surveillance by outpatient endometrial 
sampling.  Our practice was to perform histological surveillance on a six-monthly basis for 
the first two years and yearly thereafter until 5 years and then the patients were given a 
choice to have continued yearly surveillance. Women that did not adhere to this strategy were 
invited for clinic review in order to obtain long term follow up outcome.  Ethical approval 
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from the Coventry & Warwickshire Research and Ethics Committee was obtained for this 
study (LREC 09/H1211/30). 
 
For all women in the study (n = 344), baseline data were recorded for: histological subtype, 
age, ethnic background, body mass index, parity, menopausal status, medical history of 
hypertension or diabetes, use of exogenous hormones (e.g. HRT, tamoxifen) and ultrasound 
measurement of endometrial thickness for post-menopausal women.  For women on HRT we 
advised to stop it until endometrial regression was achieved and then it was restarted as 
necessary.  Tamoxifen treatment was normally continued.  Menopause was defined as a 
minimum of 12 consecutive months of amenorrhea, for which there was no other obvious 
pathological or physiological cause.  Missing data were sought also from primary care 
clinicians.  The time from baseline histology until the last follow up was also recorded for all 
patients.    
 
The primary outcome for this study was to determine the proportion of women with CH or 
ACH showing histological regression after treatment with LNG-IUS compared to oral 
progestogens.  For this assessment, the results of follow-up histological examinations were 
classified as 1) Complete Regression – atrophy of glands, oedematous fibrotic stroma or 
pseudodecidualisation, with no evidence of hyperplasia.  2) Persistence or Progression – 
failure to completely regress with evidence of CH, ACH or carcinoma.  The secondary 
outcomes we studied were the hysterectomy rate for each treatment, the time interval from 
treatment initiation to complete regression and the proportion of patients in both groups 
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diagnosed with EC during follow-up.  All outcomes were evaluated with an intention to treat 
basis. 
 
The baseline characteristics and outcomes for the LNG-IUS and oral progestogen groups 
were analysed using Mann-Whitney U tests for non-parametric data and Pearson χ2 tests for 
categorical data.  Analysis of outcomes between both treatment groups was performed by 
logistic regression to compute odds ratios (OR) with their 95% CI adjusting for potential 
confounding factors.  We adjusted for correlated confounding factors (p<0.1) with both 
treatment modality and outcome and these were incorporated into the final model.
83
  We 
constructed our survival analysis using the Cox proportional hazards model as it accounts for 
variable duration of follow-up, censoring of subjects, proportionality of event occurrence, 
and time-to-event.
99
  To convert the results of the Cox model into absolute risk estimates, we 
calculated survival within our population by using Kaplan-Meier estimates.
100,101
  Missing 
data were handled by complete case analysis for our exposure (treatment modality) and 
outcomes (regression and hysterectomy) and by multiple imputation for confounding 
variables.
102,103
  All analyses were performed using STATA Version 12.1 (Stata Corp, 
College station, TX, USA). 
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Results 
Figure 12 Schematic representation of patients included in study analysis 
 
Of the 655 women diagnosed with CH or ACH over the 12 year study period, 361 women 
were treated with progestogens (Figure 12).  We had incomplete data on follow up for 17 
women and these were excluded.  Our follow up rate was therefore 95.3% (344/361).   The 
final study group consisted of 250 women in the LNG-IUS group and 94 women in the oral 
progestogen group.  The mean length of follow up in the two groups was 66.9 ± SD 35.1 
months for the LNG-IUS versus 87.2 ± SD 45.5 for the oral progestogen group.  The duration 
of treatment with oral progestogens consisted of three (29.8%, 28/94), six (63.8%, 60/94) or 
twelve months (6.4%, 6/94) and then the treatment was stopped.  The most common type of 
progestogen therapy given was norethisterone (50%), followed by medroxyprogesterone 
acetate (43%), dydrogesterone (2%), megestrol acetate (1%) and a combination of therapies 
(4%).  Progestogen therapy was given either cyclically (32%) or continuously (68%). 
Baseline characteristics between both treatment groups were compared and found to be 
similar for all variables with the exception of age and menopause (Table 6).   
Women diagnosed with complex hyperplasia on 
endometrial biopsies in Birmingham Women’s 
Hospital (1.8.98-1.8.10) N=655 women
Women diagnosed with complex hyperplasia and 
treated with progestogens N=361 women
Excluded women (N=294) managed by
Hysterectomy n=249 women
Observation only n=21
Other therapies e.g. GnRH, OCP n=14
Loss to follow up n=10 
Excluded women with incomplete 
follow (less than 12 months) up N=17
Women diagnosed with complex hyperplasia and 
treated with progestogens N=344 women
Mirena coil n=250 Oral progestogens n=94
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Table 6 Baseline characteristics 
 
The women in the LNG-IUS group were older (mean 52.7 years ± SD 10.6 versus 48.5 ± 
11.6, p=0.001) and more often menopausal compared to the oral progestogen group (52.4%, 
131/250 versus 33%, 31/94, p≤0.001).  The body mass index was not available for 27/344 
(7.8%) patients and also the endometrial thickness was not measurable in 9/162 (5.6%) of 
post-menopausal women.     
 
 LNG-IUS 
 (n=250) 
Oral Progestogens 
(n=94) 
 
P value 
 n (%)
 
n (%)
 
 
Age (years) Mean 52.7 ± SD 10.6 Mean 48.5 ± SD 11.6 0.001 
Parity Mean 2.1 ± SD 1.5 Mean 1.7 ± SD 1.9 0.095 
BMI (kg/m
2
) Mean 33 ± SD 9.5 Mean 32.2 ± SD 8 0.493 
Endometrial thickness on USS (mm) for 
menopausal women 
Mean 9.9 ± SD 5.6 Mean 10.9 ± SD 6.4 0.245 
Ethnic Group Caucasian 196 (78.4) 72 (76.6)  
Asian 29 (11.6) 11 (11.7)  
Other 10 (4) 9 (9.6)  
Unknown 15 (6) 2 (2.1) 0.78 
Menopausal Status Premenopausal 119 (47.6) 63 (67)  
Postmenopausal 131 (52.4) 31 (33)        0.001 
Hypertensive 
 91 (36.4) 26 (27.7) 0.139 
Diabetic 
 41 (16.4) 13 (13.8) 0.551 
HRT / Tamoxifen use in 
 last 5 years 
None 199 (79.6) 81 (86.2)  
HRT 42 (16.8) 10 (10.6)  
Tamoxifen 9 (3.6) 3 (3.2) 0.165 
Endometrial Histology Atypical hyperplasia 21 (8.4) 13 (13.8)  
Complex hyperplasia 229 (91.6) 81 (86.2) 0.137 
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Regression of hyperplasia was achieved in 94.8% (237/250) of patients with LNG-IUS 
compared to 84% (79/94) of patients treated with oral progestogens (Table 7) and this 
difference was found to be statistically significant (OR=3.46, 95% CI 1.58–7.19, p=0.001).   
Table 7 Outcomes of patients treated with LNG-IUS compared oral progestogens 
    
  
LNG-IUS 
 (n=250) 
Oral Progestogens 
 (n=94) 
 
P value 
 
Odds ratio 
 
Adjusted Odds ratio 
  n (%)
 
n (%)
 
Time from diagnosis to last 
histological follow up (months) 
Mean 66.9 ± SD 35.1 Mean 87.2 ± SD 45.5 <0.001   
Regression of hyperplasia 
 
237/250 (94.8) 79/94 (84) 0.001 3.46 (1.58-7.59) 3.04 (1.36-6.79) 
- Complex hyperplasia 221/229 (96.5) 73/81 (90.1) 
- Atypical hyperplasia  16/21 (76.2) 6/13 (46.2) 
Hysterectomy Performed  55/250 (22.1) 35/94 (37.2)  0.004 0.48 (0.29-0.8) 0.48 (0.28-0.81) 
Cancer diagnosed  6/250 (2.4) 4/94 (4.3) 0.361   
 
Regression rates were higher for CH compared to ACH for both LNG-IUS (96.5%, 221/229 
vs. 76.2%, 16/21; p≤0.001) and oral progestogens (90.1%, 73/81 vs. 46.2%, 6/13; p≤0.001).  
Hysterectomy rates were also significantly lower in the LNG-IUS group compared to the oral 
group during follow up (22.1%, 55/250 vs. 37.2%, 35/94, OR=0.48, 95% CI 0.29–0.8, 
p<0.004).  From the total of 10 women (4 CH, 6 ACH) diagnosed with EC during follow up, 
7 were originally treated with LNG-IUS (6/250, 2.4%) and 4 with oral progestogens (4/94, 
4.3%; p=0.361).  They were all found to be at early stage EC (Stage Ia, G1 for 5 women and 
Ib G1 for 4 women) apart from one woman who was diagnosed with endometrioid cancer of 
the ovary (Stage Ib) according to the latest FIGO classification.
104
  The 28 women that did 
not achieve regression were strongly recommended to undergo hysterectomy from which 24 
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eventually underwent this procedure in a median time of 12.9 months from diagnosis (IQR 
10.1 to 16.4 months) and 8 were diagnosed with EC on the hysterectomy specimens (33.3%, 
8/24).  From the remaining four women, one is well and undergoing assisted reproduction 
treatment, two declined further biopsies and are currently undergoing long term clinical 
follow up only and one was lost to follow up after 18 months.  On logistic regression, age 
was found to be independently correlated with both treatment modality and the regression 
outcome.  As a potential confounder we adjusted the odds ratio for outcomes of EH 
regression and hysterectomy (Table 7).   
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Figure 13 Kaplan-Meier survival curves for all events of EH regression in women treated either with LNG-IUS or oral 
progestogens. CI = confidence interval; HR= hazard ratio. 
 
The survival analysis indicates that regression was higher with LNG-IUS at 12, 18 and 24 
months of follow up (Hazard ratio 1.48, 95% CI 1.14-1.92, p=0.002; Figure 13).  The 
majority of the women achieved regression by 24 months and specifically it was achieved in 
93.6% (221/236) of women treated with LNG-IUS and 91.1% (72/79) of women treated with 
oral progestogens by this time point.  The survival analysis for hysterectomy indicates that 
hysterectomy was less likely to happen in women treated with LNG-IUS from 12 up to 60 
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months of follow up (Hazard ratio 0.56, 95% CI 0.37-0.86, p=0.007; Figure 14).  
Specifically, by 60 months, 22% of women (55/250) treated with LNG-IUS underwent 
hysterectomy compared to 37.2% of women (35/94) treated with oral progestogens. 
Figure 14 Kaplan-Meier survival curves for all events of hysterectomy for EH in women treated either with LNG-IUS or 
oral progestogens. CI = confidence interval; HR= hazard ratio; hyst.=hysterectomy. 
 
Discussion 
To our knowledge, this is the largest study with the longest follow up period examining the 
efficacy of LNG-IUS in the treatment of EH and comparing it with the current standard 
treatment of oral progestogens.  The results of our study have shown that complete regression 
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of EH was achieved in a higher proportion of women treated with LNG-IUS (95%) compared 
to women treated with oral progestogens (84%) with, consequently, lower rates of 
hysterectomy (22% versus 38%).  Women failing to regress to normal histology had a high 
risk of cancer diagnosis at the time of the hysterectomy, which was up to 33%.  
 
The long term follow up provides valuable information about the efficacy of treatment 
modalities for CH and ACH.  The inclusion of the vast majority of eligible women and the 
size of this study eliminates potential selection bias.  We achieved a very high percentage of 
follow up (>95%) for our primary outcome of endometrial regression at 12 months and we 
reduced potential follow-up bias.  We also measured and adjusted for a large number of 
potential confounding factors.  The observational design, though, cannot exclude residual 
confounding from unmeasured variables.  Follow-up differed in the two groups and the 
retrospective inclusion of women treated with oral progestogens has introduced performance 
and verification bias.  Despite the retrospective recruitment of women treated with oral 
progestogens, women were recalled for follow up by contacting them through their primary 
care clinicians.  This reduced the amount of missing data and increased our follow up rate up 
to 95%.  Our follow up strategy with endometrial sampling on a six-monthly basis for the 
first two years and yearly thereafter ensured robust surveillance.  Pragmatic follow up visits 
were arranged on a patient-to-patient basis at variable time intervals, but the majority of 
women were followed up at least yearly.     
 
The efficacy of LNG-IUS has been assessed in a few former studies, and is consistent with 
our findings. These studies have all reported a regression rate above 90%.
15,16
  A study 
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previously published from our centre showed that the regression rate of 109 patients treated 
with LNG-IUS was 92%.
31
  Ultimately, we found that despite a larger cohort, our results for 
the regression rate with LNG-IUS are still consistent with those previously published from 
our centre.  In terms of comparing LNG-IUS efficacy with other therapies, there is only one 
other observational study which has examined the efficacy of LNG-IUS versus oral 
progestogens
32
.  Orbo et al studied the regression rate of oral progestogens (54%) and LNG-
IUS (100%).
32
  This study used a different classification system to assess the degree of 
hyperplasia, which makes it difficult to correlate their outcomes with the WHO classification 
criteria.
7
  This study also used low dosages of oral progestogens (medroxyprogesterone 
10mg/day cyclical - 10 day use/cycle), which may account for the lower rates of regression 
observed.   
 
We believe that the difference of regression and relapse rates of LNG-IUS over oral 
progestogens for the treatment of EH found in our study can be explained by the mode of 
progestogen delivery as explained before.  Additional issues of compliance (100% with 
LNG-IUS) and adverse effects such as nausea, weight gain, headaches, thrombophlebitis and 
hypertension, also limit the overall efficacy of oral progestogens.  The LNG-IUS is 
associated with higher patient satisfaction and, therefore patients are more likely to continue 
the treatment.
105
  This higher chance of patients continuing the LNG-IUS treatment may also 
explain its better efficacy in treating EH compared to oral progestogens.  In addition, the 
duration of the treatment appears also to be an important factor for achieving disease 
regression and avoiding hysterectomy.   The LNG-IUS provides a standard daily dose of 
progestogens for five years, where the oral progestogen treatment is likely to be discontinued 
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by clinicians following evidence of disease regression.  Interestingly, the duration of 
treatment with oral progestogens was usually six months (64%) and occasionally extended up 
to 12 months (6%), but regression continued during follow up and in some cases, when the 
treatment was actually stopped.  Spontaneous regression of SH and CH, even with no 
treatment, has been described before,
4
 and a study observed a spontaneous regression rate up 
to 50% during follow up.
32 
 This is likely to occur in perimenopausal women as they become 
menopausal and cease their anovulatory cycles causing oestrogen decline. 
 
Overall, the use of LNG-IUS for EH is found to be associated with higher regression and 
lower hysterectomy rates compared to oral progestogens.   This study suggests that LNG-IUS 
should be offered as initial treatment and only patients that decline it should be offered oral 
progestogens as an alternative.  However, we advise caution on the interpretation of this 
finding as the follow-up differed in the two groups and we cannot rule out  unmeasured 
residual confounding.  In view of the relatively high underlying EC rates in non-regression 
cases (up to 33%), we recommend that women undergo hysterectomy if six-monthly 
histological surveillance within 24 months from diagnosis fails to indicate regression.  The 
women with ACH are particularly at high risk and should be monitored more carefully.  The 
excellent efficacy of LNG-IUS also makes it less justifiable to offer hysterectomy as a first 
line treatment for patients with CH.   Further research should be directed in identifying 
prognostic factors that could help recognise patients that are less likely to respond to LNG-
IUS treatment.   This would facilitate careful patient selection for the LNG-IUS and will 
reduce the proportion of hysterectomies performed unnecessarily.   
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Chapter 6: Relapse of EH after conservative treatment: A cohort study 
with long term follow up. 
Abstract 
Objective  
The LNG-IUS and oral progestogens are used to treat women with endometrial hyperplasia 
and achieve regression.  There is uncertainty on further surveillance for those women as the 
risk for relapse is unknown. Our objective in this study was to determine the risk of relapse 
for women with EH treated with LNG-IUS or oral progestogens?  
Methods  
A cohort study of 219 women with CH or ACH that were treated and achieved initial 
regression with LNG-IUS (n=153) or oral progestogens (n=66) from August 1998 until 
December 2007 and followed up for more than five years.  Mean length of follow up in the 
two groups was 74.7 ± SD 31.8 months for the LNG-IUS versus 87.6 ± SD 42.2 months for 
the oral progestogen group.  We evaluated the proportion of women that relapsed or had 
hysterectomy after initial regression with LNG-IUS compared to oral progestogens by 
logistic regression adjusting for confounding.  The time from regression to relapse was 
explored through a survival analysis. 
Results  
Relapse of EH occurred in 13.7% (21/153) of women treated with LNG-IUS compared to 
30.3% (20/66) of women treated with oral progestogens (OR=0.37, 95% CI 0.18–0.73, 
p=0.005).  Relapse rates over long term follow up were lower for CH compared to ACH for 
both LNG-IUS (12.7%, 18/142 vs. 27.3%, 3/11; p=<0.001) and oral progestogens (28.3%, 
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17/60 vs. 50%, 3/6; p≤0.001).  The survival analysis indicates that relapse occurred less often 
with LNG-IUS at 12, 24, 36, 48, 60 and more than 60 months of follow up (Hazard ratio 
0.37, 95% CI 0.2-0.7, p=0.001).   There were no events of relapse after 48 months from 
regression with oral progestogens, but some women treated with LNG-IUS relapsed after 60 
months when treatment was discontinued.  Hysterectomy rates were lower in the LNG-IUS 
group during follow up (19.6%, 30/153 vs. 31.8%, 21/66, OR=0.52, 95% CI 0.27–1, p=0.05).   
EC was diagnosed in 2 (11.8%) women that had hysterectomy (n=17) because of relapse.  
We were unable to accurately estimate the cancer risk in women who relapse during follow 
up as only 17 out of 41 who relapsed underwent hysterectomy.  
Conclusion  
Relapse of endometrial hyperplasia after initial regression occurs often and long term follow 
up is advised. 
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Introduction 
In our meta-analysis we found that the LNG-IUS achieves regression in up to 92% of 
women.
95
  This meta-analysis finds that the regression with LNG-IUS is higher than with oral 
progestogens and as a result it has the potential to reduce the number of hysterectomies 
performed for this condition.
95
  In our own comparative cohort study we have discovered that 
the regression with LNG-IUS is more likely and this is the reason for fewer hysterectomies 
for women treated with LNG-IUS.
8
  The mainstay treatment for ACH is hysterectomy as 
explained before because of the high risk of progression to cancer and the possibility of 
concomitant cancer in women undergoing hysterectomy.  Hormonal therapies have also been 
used to treat ACH in young women that wish to preserve their fertility and it may be the only 
option for women with severe comorbidities.
 
 
Despite the initial regression of EH with hormonal therapies, we advised caution because of 
the possibility of relapse.
106
  In a meta-analysis for young women with ACH treated with 
hormones the summary estimate of the relapse rate was about 26%.
106
  Considering that the 
majority of the studies in the literature have short durations of follow up the risk of relapse of 
ACH following an initial regression may even be higher.  On the other hand, the majority of 
clinicians treat women with CH with hormonal therapies, but the risk of relapse for these 
women remains unknown.
106
  This prevents many clinicians from embarking on long term 
follow up.  Even though, it is known from a case-control study that women diagnosed with 
CH are at higher risk of progression to cancer than healthy women,
 
the risk of relapse and a 
strategy for following up these women remains to be defined.
107
  In this study, we have 
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conducted a cohort study with more than five years follow up for defining the relapse risk for 
women with CH and ACH treated with LNG-IUS or oral progestogens.  
 
Methods 
This was a comparative observational study.  We included all women diagnosed with CH or 
ACH that underwent treatment with LNG-IUS or oral progestogens from August 1998 until 
December 2007 in a tertiary referral Hospital in Birmingham, UK.  Patient selection has been 
described in detail in Chapter 5.  We opted to include women until December 2007 to ensure 
at least five year follow up for all participants.  Following initial regression, women were 
followed yearly thereafter for five years to ascertain if relapse occurred and then the patients 
were given a choice to have continued yearly surveillance. 
  
The primary outcome for this study was to determine the proportion of women with CH or 
ACH that had a relapse of EH or cancer after showing histological regression following 
treatment with LNG-IUS compared to oral progestogens.  Our follow up policy aimed to 
ensure a maximum rate involving also primary care clinicians.  For this assessment, the 
results of follow-up histological examinations following the initial regression were classified 
as 1) Complete Regression – atrophy of glands, oedematous fibrotic stroma or 
pseudodecidualisation, with no evidence of hyperplasia.  2) Relapse – failure to remain in 
regression with evidence of CH, ACH or carcinoma.  The secondary outcomes we studied 
were the hysterectomy rate for each treatment, the time interval from regression to relapse 
and the proportion of patients in both groups diagnosed with endometrial cancer during 
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follow-up.  All outcomes were evaluated with an intention to treat basis.  The statistical 
section is already described in Chapter 5. 
 
Results 
Figure 15 Schematic representation of patients included in study analysis 
 
During the study period, 527 women were diagnosed with CH or ACH and 260 were treated 
with progestogens (Figure 15).  We have excluded women that failed to achieve regression 
after progestogen treatment (n=24).  We have also excluded women that did not accept long 
term follow up following their initial regression (n=18) or opted for hysterectomy (n=4).  As 
a result, we have included 219 women in our study from which, 66 were treated with oral 
progestogens and 153 with LNG-IUS.  Table 8 shows the baseline characteristics of the 
women according to the type of treatment.  Women treated with oral progestogens were older 
Women diagnosed with complex hyperplasia on 
endometrial biopsies in Birmingham Women’s 
Hospital (1.8.98-1.12.07) N=527 women
Women diagnosed with complex hyperplasia and 
treated with progestogens N=260 women
Excluded women (N=267) managed by
Hysterectomy n=229 women
Observation only n=18
Other therapies e.g. GnRH, OCP n=12
Loss to follow up n=8 
Excluded women that did not regress to 
normal histology and cannot be 
assessed for relapse N=24
Women diagnosed with complex hyperplasia , 
regressed with progestogens and assessed for 
relapse with 5 year follow up N=219 women
Mirena coil n=153 Oral progestogens n=66
Excluded women that declined follow 
up following regression N=18
Excluded women that  opted for 
hysterectomy instead N=4
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and more likely to be menopausal.  The mean follow up in the two groups was 74.7 ± SD 
31.8 months for the LNG-IUS group and 87.6 ± SD 42.2 months for the oral progestogen 
group.   
Table 8 Baseline characteristics of women regressed with LNG-IUS or oral progestogens and assessed for relapse 
 
The relapse rate following regression with LNG-IUS treatment was 13.7% (21/153) and it 
was higher for ACH (27.3%, 3/11) than for CH (12.7%, 18/142).  The relapse rate following 
regression with oral progestogens was 30.3% (20/66) and similarly it was higher for ACH 
(50%, 3/6) than for CH (28.3%, 17/60).  The difference in relapse rates was significant 
 LNG-IUS 
 (n=153) 
Oral Progestogens 
(n=66) 
 
P value 
 n (%)
 
n (%)
 
 
Age (years) Mean 53 ± SD 10.1 Mean 50.4 ± SD 11.5 0.091 
Parity Mean 2.2 ± SD 1.4 Mean 2 ± SD 2.2 0.533 
BMI (kg/m
2
) Mean 33.3 ± SD 10.2 Mean 32.5 ± SD 9 0.629 
Endometrial thickness on USS (mm) for menopausal 
women 
Mean 10.2 ± SD 6.1 Mean 11.2 ± SD 7.7 0.377 
Ethnic Group Caucasian 116 (75.7) 49 (74.3)  
Asian 19 (12.5) 9 (13.6)  
Other 10 (6.6) 7 (10.6)  
Unknown 8 (5.2) 1 (1.5) 0.75 
Menopausal Status Premenopausal 75 (49) 46 (69.7)  
Postmenopausal 78 (51) 20 (30.3)        0.005 
Hypertensive 
 58 (37.9) 19 (28.8) 0.195 
Diabetic 
 23 (15) 9 (13.6) 0.788 
HRT / Tamoxifen use in 
 last 5 years 
None 121 (79.1) 56 (84.9)  
HRT 30 (19.6) 8 (12.1)  
Tamoxifen 2 (1.3) 2 (3) 0.36 
Endometrial Histology Atypical hyperplasia 11 (7.2) 6 (9.1)  
Complex hyperplasia 142 (92.8) 60 (90.9) 0.629 
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between LNG-IUS and oral progestogens (p=0.004) and this was confirmed when adjusted 
for menopause (adjusted OR= 0.34, 95% CI 0.17-0.7, Table 9).  As a result, there were less 
hysterectomies performed with LNG-IUS treatment (19.6%, 30/153) compared to oral 
progestogens (31.8%, 21/66, p=0.05).   Overall, 41 women relapsed during follow up and 
were offered hysterectomy.  Only 17 women underwent hysterectomy and two were 
diagnosed with endometrial cancer (11.8%). One woman initially diagnosed with CH and 
treated with LNG-IUS progressed to endometrioid cancer with concomitant granulosa cell 
tumour of the ovary after 36 months from initial regression.  Another woman initially 
diagnosed with ACH and treated with oral progestogens progressed to Stage Ia endometrioid 
cancer after six months from initial regression. 
Table 9 Outcomes of patients assessed for relapse following initial regression after treatment with LNG-IUS or oral 
progestogens 
  
LNG-IUS 
 (n=153) 
Oral Progestogens 
 (n=66) 
 
P value 
 
Odds ratio 
(95% CI) 
 
Adjusted Odds ratio 
(95% CI)   n (%)
 
n (%)
 
Time from diagnosis to last 
histological follow up (months) 
Mean 74.7 ± SD 31.8 Mean 87.6 ± SD 42.2 0.066   
Relapse of hyperplasia 
 
21/153 (13.7) 20/66 (30.3) 0.005 0.37 (0.18-0.73) 0.34 (0.17-0.7) 
- Complex hyperplasia 18/142 (12.7) 17/60 (28.3) 
- Atypical hyperplasia  3/11 (27.3) 3/6 (50) 
Hysterectomy Performed  30/153 (19.6) 21/66 (31.8)  0.05 0.52 (0.27-1) 0.49 (0.25-0.97) 
Cancer diagnosed  1/153 (0.65) 1/65 (1.5) 0.539   
 
The survival analysis on Figure 16 indicates that relapse occurs less frequently after initial 
regression with LNG-IUS treatment than with oral progestogens over the five year follow up 
(HR=0.37, 95% CI 0.2 to 0.7, p=0.001).  Relapse occurs also sooner with oral progestogens.  
Relapse occurred at a median time of 32.2 months ± IQR 11.3 to 57.7 months following 
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LNG-IUS treatment compared to 13.7 ± IQR 5.7 to 20.6 months following oral progestogens.  
No relapse was observed after 48 months from initial regression with oral progestogens 
compared to LNG-IUS where five women relapsed after the five year period when this 
treatment was discontinued.     
Figure 16 Kaplan-Meier survival curves for all events of EH relapse in women initially regressed after treatment with 
LNG-IUS or oral progestogens. CI = confidence interval; HR= hazard ratio. 
 
Discussion 
Management of EH with progestogens is aimed to induce endometrial regression and prevent 
women from undergoing hysterectomy.  This may be particularly appealing to young women 
wishing to preserve their fertility or women with multiple comorbidities who are poor 
surgical candidates.  However, relapse of ACH or CH following treatment with progestogens 
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is common.  The risk is higher when women are treated with oral progestogens compared to 
LNG-IUS and results in more hysterectomies. However, the differences in patient selection 
and subsequent follow up, similarly to Chapter 5, may have introduced performance and 
differential verification biases.  Despite this limitation, this study is unique in the literature as 
it follows up women for more than five years and covers the period from their initial 
regression following progestogen treatment to the time of relapse.  Our data suggest that this 
risk is high and discontinuing follow up after an initial regression is not justified.  Women 
treated with oral progestogens relapse earlier and no further events were recorded after 48 
months from the initial regression.  Women treated with LNG-IUS may relapse after five 
years when the LNG-IUS treatment is stopped and therefore we propose that if a replacement 
LNG-IUS is not carried out then these patients should be followed up for at least a further 
year.  Women that relapsed during follow up were diagnosed with endometrial cancer in up 
to 12% of cases.  
 
The design of our study and the long term follow up provides valuable information about the 
risk of relapse and aids the follow up strategy for these women.  An important limitation also 
discussed previously is the differences in inclusion of women in the two groups and 
subsequent differences in their follow up that may have contributed to the observed 
differences in relapse rates.  However, we minimised missing follow-up data for the women 
treated with oral progestogens before August 2008 by recalling them for long term 
surveillance.  We achieved a high percentage of follow up for relapse rate at 12, 24, 36, 48 
and 60 months and we reduced potential follow-up bias.  From our intended sample size we 
achieved a 98% follow up for the relapse rate at 12 months, 94% for 24 months, 88% for 36 
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months, 79% for 48 months and 73% for 60 months.  We also measured and adjusted for a 
large number of potential confounding factors.  The observational design, though, cannot 
exclude residual confounding from unmeasured variables, such as change of weight during 
follow up or new onset of diabetes.  We were also unable to accurately estimate the risk of 
cancer in women who relapse during follow up as only 17 out of 41 underwent hysterectomy.  
 
The LNG-IUS is the treatment of choice for ACH and CH but oral progestogens remain 
popular among clinicians.
96
  It has been accepted practice to treat until an endometrial 
regression is confirmed histologically.  Following this confirmation there was uncertainty 
whether they warrant further follow up.  The literature is scarce on the optimum follow up 
strategy and guidelines are lacking.  Previous studies have concentrated mostly on the time 
taken for women with ACH or CH to regress to normal endometrium.
31,32
  Two small studies 
did not report any diagnoses of endometrial cancer during follow up but did not specifically 
report on the risk of relapse during follow up.
32;47
  However, a case control study found that 
women with a previous diagnosis of ACH or CH were at higher risk of developing 
endometrial carcinoma over the long term, which may be up to 21 times higher than the 
average population risk.
107
  This may be justified from the high risk of relapse of endometrial 
hyperplasia following initial treatment.
 
 
The difference of relapse rates of LNG-IUS over oral progestogens for the treatment of EH 
found in our study can be explained by the duration of treatment.  The LNG-IUS provides a 
standard daily dose of progestogens for five years, whereas the oral progestogen treatment is 
likely to be discontinued by clinicians following evidence of disease regression.  In our 
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cohort this was commonly at six months.  Despite stopping the progestogen treatment we did 
not observe any cases of relapse after 48 months.  This is in contrast to a few relapse events 
after discontinuing LNG-IUS treatment at five years.  We are unable to explain this 
difference between the oral and LNG-IUS groups but this should highlight to the clinicians 
that relapse may occur after stopping LNG-IUS treatment after a five year period.  It is 
envisaged that if the precipitating cause for EH cease to exist during follow up, such as HRT, 
it is unlikely that EH will reoccur.  In other cases, if the cause is not abolished as it is often 
the case with obese women, the high oestrogen concentrations may be causal to the relapse of 
EH.   Further research should focus on predictors to identify women at high risk of relapse 
and prioritise their long term follow up. 
 
To conclude, this study indicates that relapse for women with ACH or CH treated with 
progestogens is common.  Discontinuing follow up following an initial regression is not 
justified and should be continued for at least five years and particularly so after LNG-IUS 
treatment is stopped.  Women who relapse during follow up should be subjected to 
hysterectomy as there may be underlying undiagnosed cancer.  
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SECTION II PROGNOSIS OF ENDOMETRIAL HYPERPLASIA 
Chapter 7: Prognostic significance of ER and PR expression in LNG-IUS 
treatment of EH: an immunohistochemical study. 
Abstract 
Objective  
To identify immunohistochemical (IHC) predictors of persistent EH when treated with LNG-
IUS. 
Methods 
We performed IHC of ER, PR, PTEN and aromatase in EH treated with LNG-IUS and 
explored their prognostic significance.  The baseline pre-treatment EH of a selected 
prospective cohort was analysed [CH (n=29) and ACH (n=5)].  Study participants were 
categorised into those that showed endometrial regression (responders, n=28) and those that 
showed non-regression or histological progression to atypia or malignancy (non-responders, 
n=6).  IHC expression was expressed as a histological score (HS).   
Results  
Responders compared to non-responders showed significantly higher histological scores for 
ER and PR.  Absence of ER and PR predicted non-responder status with likelihood ratios of 
9.33 (95% CI 2.19-39.81) and 2.92 (95% CI 1.47-5.79), respectively.  Neither PTEN nor 
aromatase expression were associated with LNG-IUS therapy responsiveness.   
Conclusion 
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Responsiveness of EH to LNG-IUS therapy may be determined through analysis of baseline 
oestrogen and progesterone receptors but these exploratory findings require confirmation in a 
larger dataset.   
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Introduction 
The principal aims of medical treatment of CH are to prevent histological progression to 
cancer, induce endometrial regression, and minimise the frequency and amount of any 
abnormal uterine bleeding.  From our study we have shown that LNG-IUS achieves such 
outcomes in more than 90% of the cases.
8
  Given EH is an oestrogen-dependent proliferation, 
there is widespread consensus, supported by experimental data, that aberrant progesterone or 
oestrogen metabolism of the endometrium may be causal to the initiation, progression and 
malignant transformation of EH.
37
  Differential expression of ER and PR could also 
contribute to the variation of efficacy in progestogen therapy of EH.  Other molecular 
pathways have been implicated in the generation of benign and malignant uterine pathology 
and these include the involvement of aromatase and PTEN.
15,26
  However, no studies have 
explored their association to the treatment or malignant progression of EH.  We assessed the 
prognostic accuracy of ER, PR, aromatase and PTEN receptor expression for predicting the 
efficacy of LNG-IUS treatment of EH over long term follow up.   
 
Methods 
Thirty-four cases of CH and ACH were selected from a prospectively collected dataset of EH 
treated by LNG-IUS.  The criteria for selection were: at least six months of endometrial 
follow up (either by endometrial biopsy or hysterectomy) following LNG-IUS 
commencement; availability of all pre-treatment baseline and interval treatment endometrial 
specimens; for each subject, all samples should have demonstrated,  in a consistent manner 
without histological reversion, either endometrial regression or persistent hyperplasia or 
histological upgrading.  Due to the overall small number of non-responders and cases with 
96 
 
atypia these cases were actively included in the study population as we felt they provided 
valuable information.  All other cases were selected at random, regardless of demographics 
or other clinical information. 
 
The prospective dataset has been previously reported
31
 and includes consecutively 
prospectively recruited women with EH treated by LNG-IUS whose treatment commenced 
from 1999 until 2004.  Endometrial sampling was performed on a three to six-month basis for 
the first year and yearly thereafter for five years.  The interpretation of baseline pre-LNG-
IUS treatment and interval treated hyperplasia histologies were made by two experienced 
gynecological pathologists according to WHO criteria.
7
   
 
The selected study women (n=34) were classified as either responders or non-responders.  
Responders were defined as subjects showing endometrial regression with no evidence of 
continuing hyperplasia.  Endometrial regression has been previously defined and denotes 
progestogen effects on the endometrium which includes: gland atrophy, glands separated by 
plump polygonal pseudodecidualised stromal cells and epithelial metaplasia.  Non-responders 
were defined as subjects showing persisting hyperplasia and/or histological upgrading to 
ACH or EC. 
 
Six 10 µm thick sections were cut from paraffin-embedded tissue blocks from baseline before 
LNG-IUS therapy EH tissue specimens for each selected study participant.  Immunostaining 
was performed upon five sections and the remaining section underwent standard 
haematoxylin and eosin staining.  Immunostaining was performed using Dako Autostainer 
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and Dako detection kit K5007 (Dako, Glostrup, Denmark) according to the manufacturer‟s 
protocol.  De-paraffinisation and antigen retrieval was achieved with W-CAP (Surgipath 
Europe Ltd) pH 8.0 in water bath at 98°C, apart from PTEN, which was immersed in Dako 
Low pH (pH 6.0) antigen retrieval fluid and heated to 98°C in water bath.  Slides were 
incubated for one hour with primary antibodies.  Mouse monoclonal anti-progesterone 
receptors (Form-A and Form-B, diluted 1:50) were purchased from Novocastra, Newcastle 
upon Tyne, UK.  Mouse monoclonal anti-oestrogen receptor –α (diluted 1:150) was 
purchased from Dako, Glostrup, Denmark.  Mouse monoclonal anti-aromatase (diluted 1:50) 
and rabbit monoclonal anti-PTEN were purchased from Serotec, Oxford, UK and Abcam, 
Cambridge, UK, respectively.  All antibodies were diluted using Dako Universal Antibody 
Diluent.  Endometrial controls for each antibody from the same patient were processed and 
analysed in parallel with immunostained endometrial samples.  Positive normal proliferative 
endometrium controls were utilized for ER, PR, and PTEN and as a negative control for 
aromatase expression.   
 
For ER, PR, glandular and stromal staining was recorded using a semi-quantitative 
histological score (HS).  Aromatase expression in glandular cytoplasm was scored as absent 
or present.  Staining with PTEN was assessed for the absence or presence of PTEN-null 
glands.  The HS incorporates both the intensity and the distribution of specific staining and 
its methodology has been validated by another group.
108
  The HS equates to  (Pi x i)/100, 
where Pi denotes the percentage of stained cells and i denotes the intensity of the staining 
ranging.  We used a modified version of the HS, which we developed, such that the intensity 
of staining (i) was scored in an ordinal manner 0–3: the group assigned 3 displayed strong 
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staining intensity compared to the corresponding normal endometrium; the group assigned 2 
displayed moderate staining intensity, equivalent to normal endometrium; the group assigned 
1 displayed weak staining intensity; and the group assigned 0 was negative for staining.  To 
interpret the results in an easier manner we subdivided the percentage staining (Pi) into four 
ordinal groups: 0 (<5% of cells), 1 (5-25% of cells, very focal), 2 (25%-75% of cells, focal) 
and 3 (>75% of cells; diffuse).  Local ethics approval was obtained from the South 
Birmingham Research and Ethics Committee prior to the commencement of this study 
(LREC 2002/057). 
 
The level of intra-observer agreement was calculated using Cohen‟s kappa index ± Standard 
Error (k ± SE).  The strength of association for biomarker expression and responder/non-
responder status to LNG-IUS therapy was analysed using non-parametric tests (Mann 
Whitney U and chi-squared tests).  Corresponding likelihood ratios (LR) were generated 
based on the presence or absence of histological biomarker expression.  All statistical tests 
were two-sided at the 5% level of significance and were performed using SPSS Version 16.0 
for Windows (Release 16.0.1, 15 Nov 2007, SPSS Inc.). 
 
Results 
The baseline characteristics of the study group [CH (n=29) and ACH (n=5)] are shown in 
Table 10.  The median follow-up for all study participants was 26 months (95% CI 23.1-
36.8).  The agreement regarding histological scoring between the two histopathologists was 
84.5% (K statistic = 0.811 ± 0.026).   
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Table 10 Baseline characteristics* 
Age 
BMI (kg/m
2
) 
Parity 
Nulliparous 
Menopausal 
Hypertensive 
Diabetic 
Mean 51.9; Standard Deviation 9.1; Range 36-77 
Mean 32.6; Standard Deviation 7.6; Range 21-49  
Mean 1.8; Standard Deviation 1.5; Range 0-6  
9 (26.5) 
18 (52.9) 
14 (41.2) 
5 (14.7)   
Non-atypical complex 
Atypical complex 
29 (85.3) 
5 (14.7) 
*Values in parentheses are percentages unless stated otherwise 
   
The majority of study participants responded to LNG-IUS therapy (n=28 responders; n=6 
non responders).  The median time interval for responders was 9.9 months (95% CI 4.8-
14.9).  Of the six non-responders: four demonstrated persistent hyperplasia, one upgraded 
from CH  to ACH (at five months of LNG-IUS therapy) and one upgraded from ACH to 
well-differentiated FIGO Stage Ia EC (at 10 months of LNG-IUS therapy).  Hysterectomies 
were performed in all six non-responders. 
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Table 11 The correlation of the baseline pre-treatment expression of biomarkers to LNG-IUS therapeutic responsiveness 
 Response to LNG-IUS 
Responders (n = 28) Non-responders (n = 6) p value* 
Histology  Complex 25 (86.2) 4 (13.8) 0.205 
Atypical 3** (60) 2 (40)  
ER Present 26 (92.9) 2 (7.1) 0.004 
Absent 2 (33.3) 4 (66.7)  
PR (A or B) Present 20 (95.2) 1 (4.8) 0.021 
Absent 8 (61.5) 5 (38.5)  
Aromatase Present 6 (100) 0 0.562 
Absent 22 (78.6) 6 (21.4)  
PTEN Present 17 (81) 4 (19) 0.475 
Absent 11 (84.6) 2 (15.4)  
Statistically significant associations are in bold and values in parentheses are percentages 
*p value was calculated by χ² test or Fisher‟s exact test, where appropriate, p value < 0.05 is considered 
significant,  
**Three out of five women with atypical hyperplasia with complete response to LNG-IUS had strong ER and 
PR (A, B) expression.  
 
Responders exhibited significantly higher quantitative HS for ER (2.21 ± SD 0.9 vs. 1.04 ± 
SD 1.05, p=0.026), PRA (2.04 ± SD 0.92 vs. 1.12 ± 0.92, p=0.042) and PRB (1.96 ± SD 0.92 
vs. 0.88 ± SD 0.89, p=0.011) compared to the non-responders.  The absence or presence of 
atypia, ER, PR (either A or B), aromatase, PTEN expression in relation to responder or non-
responder status is depicted in Table 11.  Responders exhibit significantly higher proportions 
of ER and PR expression than non-responders.  Histological atypia (compared to non-atypia), 
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presence of aromatase, or presence of PTEN, were not significantly associated with LNG-
IUS responsiveness (Table 12).  The absence of ER and PR expression predicted non-
responder status with likelihood ratios of 9.33 (95% CI 2.19-39.81,) and 2.92 (95% CI 1.47-
5.79), respectively (Figure 12).  
Table 12 Prediction of LNG-IUS therapeutic response 
Markers for responders to 
LNG-IUS* 
LR Lo CI 95% Up CI 95% 
 
No atypia 1.34 0.75 2.39 
ER (+) 2.79 0.89 8.68 
PR (+) 4.29 0.71 26.04 
Aromatase (-) - - - 
PTEN (+) 1.18 0.35 3.99 
Markers for non-responders to 
LNG-IUS* 
LR Lo CI 95% Up CI 95% 
Atypia 3.11 0.66 14.76 
 
 
 
 
ER (-) 9.33 2.19 39.81 
PR (-) 2.92 1.47 5.79 
Aromatase (+) 1.27 1.05 1.54 
PTEN (-) 1.1 0.58 2.08 
Statistically significant associations are in bold 
Numbers are likelihood ratios with the respective confidence intervals 
* (+) and (-) intend the presence or absence of the biomarker 
respectively  
 
Discussion 
This study demonstrates that responsiveness of EH to LNG-IUS therapy may be determined 
through analysis of baseline pre-treatment ER and PR status of the EH.  The ER and PR 
status was found to be of a higher predictive value than the presence or absence of 
cytological atypia.  Neither PTEN nor aromatase expression were associated with LNG-IUS 
therapy responsiveness.  However, the conclusions are only applicable in the context of the 
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patient population described in this paper since the sample was not representative of the 
general population of EH patients.  It should also be noted that the higher 18% non-response 
rate reported in this paper should not be assumed to be epidemiologically representative 
because of the selected sample and small number of cases.   
 
Our study is original as we believe it to be the first study to explore prognostic biomarkers 
for EH treated by LNG-IUS.  Selecting participants that possessed a mean duration of nearly 
two years of endometrial histology follow up, with consistent trends in their histological 
sampling analysis, helped to ensure greater validity and biological discrimination between 
responder and non-responder status with LNG-IUS therapy.  The association of ER and PR 
expression to LNG-IUS responsiveness was observed in both semi-quantitative (histological 
scoring) and binary presence/ absence histological descriptor systems.  This implies the 
observation is likely to be reliable.  Furthermore, the study design incorporates the analysis of 
the pre-treatment EH specimen.  This ensures the study design is pragmatic and clinically 
useful, as it intends to recreate the prognostic analysis that may be applied in future clinical 
management approaches for women with CH.  
 
We accept there may be limitations in our study that lessens the reliability of our conclusions.  
Our study sample size is small and our estimate is likely to be unstable and also may be 
underpowered to detect statistically significant differences in biomarker expression.  In 
particular, our absence of showing a prognostic role for aromatase or PTEN should not 
preclude exploration of their roles in future hyperplasia research.  The small study sample 
size also precluded our ability to perform multivariate regression analysis to correct for 
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known confounding influences from socio-demographic (e.g. BMI, parity) factors and inter-
relationships between biomarkers.  
 
Our discovery of a prognostic association for ER and PR expression with EH is not 
unexpected and has biological plausibility.  The unopposed action of oestrogen is causal to 
EH and the progestogens induce regression of EH by antagonising the oestrogen effect on the 
endometrium.
97
  Ferenczy et al found the likelihood of response to progestogens to be 
directly related to the absence of cytological atypia.
36
  Our study suggests that a molecular 
receptor-based classification for EH may have greater clinical prognostic value than that 
based on traditionally used cyto-architectural histological description (i.e. presence of atypia, 
complex architecture).  Our study contrasts with previous studies that have failed to show a 
relationship between sex steroid receptor status and response to oral progestogens.
39
  It is 
possible that the progestogen type, dosage, and method of drug delivery for these studies 
were inappropriate to achieve optimum endometrial regression, and the LNG-IUS used in our 
study may have superior therapeutic efficacy.  Nilsson et al compared the levonorgestrel 
concentrations in the uterine mucosa by different therapeutic regimens.
33
  The dose of 
levonorgestrel provided by the intrauterine device was reported to exceed that of the 
traditional systemic treatment by several-fold.  In combination with presumed lower efficacy, 
the small sample sizes of the previously reported oral progestogen studies meant that, overall, 
they were unable to detect a significant relationship between sex steroid receptor expression 
and EH treatment responsiveness.  
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We accept there is a need for further confirmatory research to validate the findings of our 
exploratory study.  It is important to identify the proportion of women who fail to respond to 
LNG-IUS and improve patient selection for this therapy.  As a result, women at risk of 
treatment failure or malignant transformation may be offered closer endometrial surveillance 
or hysterectomy.  Nonetheless, we believe this study may serve as an impetus for future 
research on the identification and evaluation of a clinical prognostic model for EH in order to 
improve health outcomes associated with this pre-malignant condition.  Such a model may 
incorporate and integrate biodemographic parameters (e.g. age, BMI, parity), histological 
cyto-architecture classification and molecular phenotyping.  Furthermore, identifying a 
particular „molecular signature‟ may provide a better understanding of the aetiopathology of 
EH and help design novel treatment strategies (e.g. combination therapies) for both 
hyperplasia and uterine cancer. 
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Chapter 8: Prediction of regression and relapse of EH treated with 
LNG-IUS or oral progestogens: A cohort study. 
Abstract 
Objective To identify predictors and to estimate their prognostic accuracy for regression and 
relapse of endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system 
or oral progestogens. 
Methods This was a cohort study of women treated with levonorgestrel-releasing intrauterine 
system or oral progestogens for complex hyperplasia or atypical complex hyperplasia for 
women wishing to preserve their fertility or those who were unfit for surgery.  Hazard ratios 
with the Cox proportional hazards model and Kaplan-Meier survival estimates for 
independent predictors were calculated. 
Results   
Regression was evaluated in 344 women over a 12-year period with a median follow-up of 
58.8 months (interquartile range [IQR] 38.4–96.4, range 12–148.2) for levonorgestrel-
releasing intrauterine system compared with 95.1 months (IQR 41.6–124.6, range 13.2–162) 
for oral progestogens.  In women treated with levonorgestrel-releasing intrauterine system for 
complex hyperplasia, we found that 221 women regressed (96.5%, 221/229) and body mass 
index (BMI) 35 or higher was associated with failure to regress (hazard ratio [HR] 5.51, 95% 
confidence interval [CI] 1.05–28.87, p=0.043).  Relapse was evaluated in 219 women over a 
9-year period with median follow-up of 67 months (IQR 50.4–103.5, range 14.5–146.4) for 
levonorgestrel-releasing intrauterine system and 96.8 months (IQR 62.3–122, range 6–151.5) 
for oral progestogens.  In women treated with levonorgestrel-releasing intrauterine system for 
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complex hyperplasia, we found that 124 women relapsed (87.3%, 124/142) and BMI 35 or 
higher was found to be a strong independent predictor of relapsed endometrial hyperplasia 
(HR 18.93, 95% CI 3.93–91.15, p<0.001).  Only 3.3% of women with complex hyperplasia 
treated with levonorgestrel-releasing intrauterine system and with BMI less than 35 relapsed 
during long term follow-up compared with 32.6% of women with BMI 35 or higher.  
Conclusion  
BMI 35 or higher is strongly associated with failure to regress and relapse of complex 
hyperplasia treated with levonorgestrel-releasing intrauterine system.  
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Introduction 
In our previous study, we found that women with EH treated with LGN-IUS or oral 
progestogens often relapse following their initial regression and this occurs more often with 
oral progestogens than with LNG-IUS.
109  
In 1989, Ferenczy et al found that women with 
cytological atypia were less likely to achieve endometrial regression and were also more 
likely to relapse during follow up.
36
  BMI, age, menopause and diabetes are associated with 
EH
111
 and could also represent prognostic markers for the outcomes of endometrial 
regression or relapse of EH treated conservatively, but these have not yet been investigated.  
In this study, our objective is to investigate the predictive ability of clinical characteristics for 
regression and relapse of EH treated with LNG-IUS or oral progestogens.  
 
Methods 
This was a cohort study.  We included all women diagnosed with CH or ACH that underwent 
treatment with LNG-IUS or oral progestogens from August 1998 until December 2010 for 
the outcome of regression (n=344) as described in Chapter 5.  For the outcome of relapse we 
opted to include women from August 1998 until December 2007 to ensure at least five year 
follow up for all participants (n=219) and the methodology is described in detail in Chapter 6.  
The primary outcome for this study was to determine the prognostic value of baseline clinical 
characteristics for women with CH or ACH treated with LNG-IUS or oral progestogens to 
predict regression and relapse.  For this assessment, the results of follow-up histological 
examinations were classified as described in Chapters 5 and 6. The secondary outcomes we 
studied were the time interval from treatment initiation to complete regression and from 
regression to relapse during follow-up.  For the outcome of regression we included all 
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women diagnosed with CH or ACH who underwent treatment with levonorgestrel-releasing 
intrauterine system or oral progestogens from August 1998 to December 2010 (n=344), and 
for the outcome of relapse until December 2007 to allow for at least five years of follow-up 
(n=219).  All outcomes were evaluated with an intention to treat basis. 
 
 
The baseline characteristics and outcomes for the LNG-IUS and oral progestogen groups 
were analysed using Mann-Whitney U tests for non-parametric data and Pearson χ2 tests for 
categorical data.  For variables with a Gaussian distribution we report means and SDs and for 
skewed data medians and IQR.  We performed survival analysis using the Cox proportional 
hazards model as it accounts for variable duration of follow-up, censoring of subjects, 
proportionality of event occurrence, and time-to-event.
99
  We computed the proportional 
changes in hazard for predicting variables and converted the results of the Cox model into 
absolute risk estimates.  We calculated survival within our population by using Kaplan-Meier 
estimates for independent predictor variables.
100,101
  Missing data were handled by complete 
case analysis for our outcomes (regression and relapse) and by multiple imputation for 
predicting variables.
102,103
  All analyses were performed using STATA Version 12.1 (Release 
January 2012, STATA Corporation). 
 
Results 
Predicting regression of EH 
Patient inclusion, follow up, baseline characteristics and regression rates are described in 
Chapter 5.  Regression was achieved more often for women with CH (96.5%, 95 CI 93.3-
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98.2, 221/229 for levonorgestrel-releasing intrauterine system and 90.1%, 95% CI 81.7-94.9, 
73/81 for oral progestogens) than for ACH (76.2%, 95% CI 54.9-89.4, 16/21 for 
levonorgestrel-releasing intrauterine system and 46.2%, 95% CI 23.2-70.9, 6/13 for oral 
progestogens).  Women with CH treated with levonorgestrel-releasing intrauterine system 
more often had a BMI of 35 or higher (HR 5.51, 95% CI 1.05-28.87, p=0.043, Table 13).  We 
did not identify significant predictors for women treated with oral progestogens or for women 
with ACH. 
 
Table 13 Univariate analysis for the prediction of regression of CH when treated with LNG-IUS or oral progestogens. 
Prognostic Variable 
Levonorgestrel-Releasing Intrauterine System 
 (n=250) 
Oral Progestogens 
 (n=94) 
Persisted 
Hyperplasia 
(n=8) 
Regressed 
Hyperplasia  
(n=221) 
Hazard Ratio 
(95% CI) 
P  
Persisted 
Hyperplasia 
(n=8) 
Regressed 
Hyperplasia 
(n=73) 
Hazard Ratio 
(95% CI) 
P 
Age 
Younger 
than 40 
2 (25) 13 (5.9) 1  2 (25) 17 (23.3) 1 
 
 40–60 6 (75) 166 (75.1) 0.54 (0.11-2.79) 0.464 5 (62.5) 46 (60.3) 0.68 (0.13-3.66) 
0.657 
 
Older than 
60 
0  42 (19) NA NA 1 (12.5) 14 (16.4) 0.7 (0.63-7.8) 0.773 
Parity Nulliparous 3 (37.5) 40 (18.1) 1  3 (37.5) 
28 (34.3) 1  
 1-2 children 3 (37.5) 104 (47.1) 0.36 (0.07-1.82) 0.218 2 (25) 
25 (36.2) 0.88 (0.14-5.38) 0.892 
 
3 or more 
children 
2 (25) 77 (34.8) 0.41 (0.06-2.58) 0.342 3 (37.5) 28 (38.4) 1.32 (0.26-6.68) 0.74 
Ethnicity White 5 (62.5) 174 (78.7) 1  6 (75) 
54 (74) 1  
 Asian 0   27 (12.2) NA NA 1 (12.5) 
9 (12.3) 1.04 (0.12-8.79) 0.971 
 Other 3 (37.5) 20 (9.1) 0.87 (0.16-4.63) 0.868 1 (12.5) 
10 (13.7) 0.73 (0.09-6.11) 0.772 
Diabetes 1 (12.5) 34 (15.4) 1.13 (0.14-9.39) 0.912 1 (12.5) 
11 (15.1) 0.48 (0.06-4.02) 0.502 
Hypertension 1 (12.5) 77 (34.8) 0.58 (0.07-4.87) 0.62 3 (37.5) 
20 (27.4) 1.83 (0.43-7.75) 0.411 
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Menopause 4 (50)  112 (50.7) 2.08 (0.46-9.43) 0.34 2 (25) 
25 (34.3) 0.69 (0.14-3.43) 0.647 
Hormone therapy or 
tamoxifen use 
2 (25) 44 (19.9) 2.5 (0.48-13) 0.277 0 11 (15.1) NA NA 
Body mass index 35 or 
higher 
5 (62.5) 65 (31) 5.51 (1.05-28.87) 0.043 4 (57.1) 15 (24.6) 2.4 (0.54-10.79) 0.252 
Endometrial thickness 
greater than 9mm 
1 (20) 88 (46.8) 0.25 (0.03-2.36) 0.227 4 (57.1) 28 (48.3) 1.24 (0.28-5.57) 0.779 
* Data are n (%) unless otherwise specified. CI, confidence interval. 
 
Predicting relapse of EH 
Patient inclusion, follow up, baseline characteristics and regression rates are described in 
Chapter 6.  Women with relapse of CH in the levonorgestrel-releasing intrauterine system 
group were more often diabetic (33.3% compared with 11.3%, HR 2.91, 95% CI 1.09-7.76, 
p=0.033; Table 14), had an endometrial thickness greater than 9mm (75% compared with 
45.7%, HR 3.35, 95% CI 1.1-10.4, p=0.037), and more often had a BMI 35 or higher (82.4% 
compared with 25%, HR 13.37 95% CI 3.8-46.7, p<0.001).  In multivariate analysis of 
women with CH treated with levonorgestrel-releasing intrauterine system, BMI 35 or higher 
was found to be a strong independent predictor of relapsed endometrial hyperplasia (HR 
18.93, 95% CI 3.93-91.15, p<0.001; Table 15).  The cumulative event rates in Figure 17 
show that only 3.3% of those women with BMI less than 35 will relapse during long term 
follow-up compared with 32.6% of women with BMI 35 or higher.  One woman in the 
former group that relapsed by 52 months had a BMI of 34.2 and in this dataset, after 24 
months from diagnosis, no woman with BMI less than 34 relapsed after initial regression 
with levonorgestrel-releasing intrauterine system. 
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Table 14 Univariate analysis of Hazard ratios for the prediction of relapse of CEH when treated with LNG-IUS or oral 
progestogens 
 
Prognostic Variable 
Levonorgestrel-Releasing Intrauterine System 
 (n=250) 
Oral Progestogens 
 (n=94) 
Relapsed 
Hyperplasia 
(n=18) 
Regressed 
Hyperplasia  
(n=124) 
Hazard Ratio 
(95% CI) 
P  
Relapsed 
Hyperplasia 
(n=17) 
Regressed 
Hyperplasia 
(n=43) 
Hazard Ratio 
(95% CI) 
P  
Age 
Younger 
than 40 
0 8 (6.5) 1  2 (11.8) 10 (23.3) 1  
 40–60 14 (77.8) 97 (78.2) NA NA 11 (64.7) 27 (62.8) 2.47 (0.55-11.18) 
0.239 
 
Older than 
60 
4 (22.2) 19 (15.3) NA NA 4 (23.5) 6 (13.9) 3.18 (0.58-17.4) 0.182 
Parity Nulliparous 3 (16.7) 20 (16.1) 1  6 (35.3) 
15 (34.9) 1  
 1–2 children 10 (55.6) 56 (45.2) 0.94 (0.26-3.45) 0.931 7 (41.2) 
15 (30.2) 1.19 (0.4-3.56) 0.749 
 
3 or more 
children 
5 (27.8) 48 (38.7) 0.68 (0.16-2.86) 0.601 4 (23.5) 15 (34.9) 0.62 (0.18-2.21) 0.464 
Ethnicity White 18 (85.7) 109 (83.2) 1  9 (47.4) 
40 (83.3) 1  
 Asian 2 (9.5) 13 (9.9) 1 (0.23-4.37) 0.995 6 (31.6) 
6 (6.3) 4.36 (1.54-12.36) 0.006 
 Other 1 (4.8) 9 (6.9) 0.59 (0.08-4.44) 0.61 4 (21) 
5 (10.4) 2.29 (0.7-7.45) 0.169 
Diabetes 6 (33.3) 14 (11.3) 2.91 (1.09-7.76) 0.033 4 (23.5) 
4 (9.3) 1.96 (0.64-6.01) 0.24 
Hypertension 9 (50) 41 (33.1) 2.33 (0.92-5.9) 0.075 5 (29.4) 
13 (30.2) 1.43 (0.5-4.07) 0.508 
Menopause 9 (50)  61 (49.2) 1.1 (0.43-2.77) 0.847 7 (41.2) 
10 (23.3) 1.98 (0.75-5.21) 0.165 
Hormone therapy or 
tamoxifen use 
1 (5.6) 29 (23.4) 0.16 (0.02-1.22) 0.078 3 (17.7) 6 (14) 1.19 (0.34-4.16) 0.781 
Body mass index 35 or 
higher 
14 (82.4) 29 (25) 13.37 (3.83-46.69) <0.001 5 (41.7) 9 (25.7) 1.67 (0.53-5.27) 0.381 
Endometrial  
thickness  greater than 
9mm 
12 (75) 48 (45.7) 3.35 (1.08-10.4) 0.037 6 (40) 16 (48.5) 0.9 (0.32-2.54) 0.844 
* Data are n (%) unless otherwise specified. CI, confidence interval. 
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Table 15 Multivariate analysis of Hazard ratios for the prediction of relapse of CH when treated with LNG-IUS or oral 
progestogens. 
Prognostic Variable 
Levonorgestrel-Releasing Intrauterine 
System 
(n=250) 
Hazard Ratio (95% CI) P  
Diabetes  0.99 (0.32-3.11) 0.991 
BMI 35 or higher 18.93 (3.93-91.15) <0.001 
Endometrial thickness  greater than 9mm 2.73 (0.82-9.16) 0.103 
CI, confidence interval.  
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Figure 17 Kaplan-Meier survival curves for all events of CEH relapse in women treated either with LNG-IUS. CI = 
confidence interval; HR= hazard ratio. 
 
 
Discussion 
In this study, we found that morbid obesity (BMI>35) is strongly associated with relapse of 
CH after initial regression with LNG-IUS treatment.  This is independent of the presence of 
diabetes or endometrial thickness in these women.  This study also finds a weak association 
with BMI 35 or higher and failure to regress CH when treated with levonorgestrel-releasing 
intrauterine system.  No predictors for regression or relapse for women treated with oral 
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progestogens and for women initially diagnosed with atypical complex hyperplasia were 
identified. 
 
We have previously described that the LNG-IUS is more successful treatment for women 
with EH than oral progestogens.
8;95
  It induces initial regression more often than oral 
progestogens and women are less likely to relapse during follow up compared to oral 
progestogens.
8;109
  However, relapse is common with both therapies and long term follow up 
is suggested.
109
  From this study we can conclude that not all women need long term follow 
up when treated with LNG-IUS.  The majority of women can be safely reassured that relapse 
is rare.  The women that would benefit from long term follow up are women with raised BMI 
over 35, as almost one out of three will relapse.  The reason appears to be that the excess of 
endogenous oestrogens persists over time and takes the toll in the antagonism with the 
Levonorgestrel of the LNG-IUS.  The hypothesis of excess body weight causing endometrial 
proliferation through oestrogen excess and chronic hyperinsulinemia is not new and has 
biological coherence.
111
  This suggests that this modifiable risk factor for EH may require 
further intervention to prevent relapse. 
 
The cohort design for women treated with LNG-IUS with the long term follow up allows the 
accurate estimation of the predictive ability of clinical characteristics to predict regression or 
relapse.  We involved primary care clinicians in the data collection and follow up and this 
resulted in our high follow up rate and our dataset with very few missing data.  We have 
measured many variables that may confound our results and we have adjusted our estimates 
where necessary.  Unfortunately, we did not engage in repeated measures of variables during 
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follow up that may differ from the baseline.  For example, we did not monitor the BMI 
during the follow up and only values at the baseline were used for our analysis.  The majority 
of the predictors reported in our study are not found to be associated with regression or 
relapse.  However, our study has less than 80% power for avoiding type II error and there is a 
high likelihood that the predictors we have investigated may represent false negatives.  
Specifically, for women treated with oral progestogens or initial diagnosis of atypical 
complex hyperplasia our sample size is particularly small to draw conclusions about the 
predictive ability of the exposures investigated. This study has implications in clinical 
practice as it aids prognosis and helps decide a strategy for surveillance of women with CH.  
We have suggested that all women with CH should be followed up for at least 24 months to 
establish if regression occurs.  Following initial regression after 24 months, we suggest long 
term surveillance for women with levonorgestrel-releasing intrauterine system and BMI 35 or 
higher for further 60 months (five years), resulting in a total of seven years of follow-up.  
Women treated with oral progestogens should be followed up for further 48 months as 
relapse is more common, but no woman relapsed after this cut-off, of a total of six years.
109
  
We cannot make conclusions on the follow-up for ACH from this study, but the risk for 
failure to regress and relapse is likely to be higher and long term follow-up is advised.  Our 
experience requires external validation in other institutions to ensure our findings can be 
generalised and applied.  Our next study is focusing on biomarkers that could aid the 
prognostic ability of predictors such as BMI and improve its accuracy. 
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Chapter 9: Predictive ability of Oestrogen (ER), progesterone (PR), 
COX-2, Mlh1, and Bcl-2 expression for regression and relapse of 
endometrial hyperplasia treated with LNG-IUS: a cohort study. 
Abstract 
Objective  
To test the predictive ability of immunohistochemical oestrogen (ER), progesterone (PR), 
COX-2, Mlh1, and Bcl-2 expression for predicting the outcomes of regression and relapse in 
women with endometrial hyperplasia treated with the Levonorgestrel-releasing intrauterine 
system (LNG-IUS).  
Methods  
We included all women diagnosed with CH or ACH that underwent treatment with LNG-IUS 
from August 1998 until September 2008.  Immunohistochemistry was performed with 
conventional methods and recorded using a semi-quantitative score (Q score) by two blinded 
assessors.  Women were followed with endometrial biopsies to record regression and relapse.  
The biomarker predictive ability was analyzed using the Cox proportional hazards model.     
Results  
The median follow-up was 72.1 months (IQR 59.1-89.8).  The Q score agreement between 
assessors was 82.6% (K statistic = 0.801 ± 0.036).  The majority of study participants 
initially regressed to normal endometrium following LNG-IUS therapy (n=164 regressed; 
n=10 persisted).   From the 164 women that regressed with LNG-IUS we were able to assess 
152 women for relapse from which 18 relapsed.  We found a weak association for persisted 
endometrial hyperplasia with ER and PR expression with Q score on the 5
th
 and 10
th
 centile. 
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No associations were found for COX-2, Mlh1 and Bcl-2 protein expression for regression 
and for any of the biomarkers for relapse. 
Conclusion 
We found that poor expression of ER and PR is weakly associated with persisting 
endometrial hyperplasia and COX-2, Mlh1, and Bcl-2 expression are not predictive.  None of 
the biomarkers is predictive for relapse in women with endometrial hyperplasia treated with 
LNG-IUS. 
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Introduction 
EH is considered to be an oestrogen-dependent benign disease of the endometrium.
112
  
Aberrant progesterone or oestrogen metabolism of the endometrium may be causal to the 
initiation, progression and malignant transformation of EH.
112
  We have already generated a 
hypothesis that the lack of ER and PR can predict poor response to treatment.
113
  However, 
the key step to this transformation to the majority of the cases appears to be local oestrogen 
production from androgens catalysed by the aromatase enzyme.
12,15
  There is a strong linear 
association between aromatase and expression of COX-2 in uterine and breast cancer 
specimens, resulting in a complex paracrine and/or autocrine signalling pathway effecting 
abnormal oestrogen synthesis.
12,15
  COX-2 is the rate-limiting enzyme in the prostaglandin 
biosynthetic pathway that stimulates oestrogen biosynthesis and higher COX-2 expression 
has been reported in hyperplastic or malignant endometrium than in normal.
13,16,17
  COX-2 is 
significantly associated with aromatase expression in EC, which suggests that intra-
endometrial oestrogen production promotes progression of EH to cancer.
18
  There is a strong 
linear association between aromatase and cyclo-oxygenases in breast cancers and 
combinations of aromatase and COX-2 inhibitors are now being used in therapeutic trials for 
breast cancer.
17
  Hence, the assessment of aromatase/COX-2 activity and steroid receptor 
status is potentially a key marker for targeted hormonal treatment of endometrial lesions 
when diagnosed early during cancerogenesis. 
 
The abnormalities in the oestrogen pathway are not the only causative features for EH and its 
malignant potential.  The angiogenesis, inhibition of apoptosis and DNA mismatch-repair 
mechanism or activation of oncogenes are the pathways most commonly described to be 
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involved in EH.  It has been shown that the altered expression of proteins, such as Bcl-2, may 
play an important role by affecting apoptosis of hyperplastic cells.
19
  The abnormal 
methylation of Mlh1 is the commonest event in EH that generates microsatellite instability 
(MSI) due to defects of the DNA mismatch-repair mechanism.
25
  Oestrogens may increase 
the rate of mutagenesis of Mlh1 through free radical formation as well as its inherent 
proliferative influence.
25
  The combination of these pathways seems to orchestrate the 
progression of EH to cancer with oestrogens masterminding the process.  The expression 
analysis of the above biomarkers currently helps understand the pathogenesis of EH and the 
pathways involved during this process.  However, the evidence on their predictive ability for 
response to progestogen treatment has been limited.
114
  In this study, we wish to test the 
hypothesis that the differential expression of IHC markers for ER, PR, COX-2, Mlh1, and 
Bcl-2 may predict regression or relapse of EH with LNG-IUS treatment over long term 
follow up.   
 
Methods 
Study population 
This was a cohort study.  We included all women diagnosed with CH or ACH that underwent 
treatment with LNG-IUS from August 1998 until December 2007 in a tertiary referral 
Hospital in Birmingham, UK.  We have excluded women with no follow up histology, 
insufficient tissue for IHC and inadequate IHC for scoring.  The histopathological diagnoses 
were undertaken by two experienced gynaecological pathologists working independently; 
referral to the other pathologist for a second opinion was made in cases where there was 
diagnostic doubt, and a mutual consensus was then achieved.  Women were reviewed 
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following diagnosis and were offered LNG-IUS (Mirena
®
, Bayer Healthcare Inc.), oral 
progestogens or hysterectomy as part of our routine clinical practice.  Women diagnosed with 
ACH were counselled and offered a hysterectomy.  Women who declined surgery or who 
were medically unfit to undergo surgery were offered LNG-IUS or oral progestogens.  We 
included in this study only women opting for treatment with LNG-IUS.  Study participants 
underwent endometrial histological surveillance by outpatient endometrial sampling.  
Histological surveillance was performed on a six-monthly basis for the first two years and 
yearly thereafter for five years and then the patients were given a choice to have continued 
yearly surveillance. Women that did not adhere to this strategy were invited for clinic review 
in order to obtain long term follow up outcome.  Ethical approval from the Coventry & 
Warwickshire Research and Ethics Committee was obtained for this study (LREC 
09/H1211/30). 
 
For all women in the study, baseline data were recorded as described in Chapter 5.  The 
primary outcome for this study is to determine the prognostic value of ER, PR, COX-2, 
Mlh1, and Bcl-2 expression for women with CH or ACH treated with LNG-IUS to predict 
regression and relapse.  For this assessment, the results of follow-up histological 
examinations were classified as described in Chapters 5 and 6. 
 
The biomarker predictive ability was analysed using descriptive statistics and Pearson χ2 test 
for categorical data.  For variables with a Gaussian distribution we report means and SDs and 
for skewed data medians and IQRs.  We performed survival analysis using the Cox 
proportional hazards model  to estimate the proportional changes in hazard for predicting 
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variables, as it accounts for variable duration of follow-up, censoring of subjects, 
proportionality of event occurrence, and time-to-event.
99
  Missing data were handled by 
complete case analysis for our predicting markers and outcomes (regression and relapse).  
The level of intra-observer agreement was calculated using Cohen‟s kappa index ± Standard 
Error (k ± SE).  All analyses were performed using STATA Version 12.1 (Release January 
2012, STATA Corporation). 
 
IHC  
Six 5 µm thick sections were serially cut from formalin fixed paraffin-embedded tissue 
blocks from baseline pre-LNG-IUS treated EH tissue specimens for each selected study 
participant.  Immunostaining was performed upon five sections and the remaining section 
underwent standard haematoxylin and eosin staining.  Immunostaining was performed using 
Dako Autostainer and Dako detection kit K5007 (Dako, Glostrup, Denmark) according to the 
manufacturer‟s protocol.  De-paraffinisation and antigen retrieval was achieved with W-CAP 
(Surgipath Europe Ltd) pH 8.0 in water bath at 98°C.  Slides were incubated for one hour 
with primary antibodies.  All antibodies were diluted using Dako Universal Antibody 
Diluent.  Primary antibodies used were mouse monoclonal anti-estrogen receptor–α , clone 
1D5 (Dako, Glostrup, Denmark; 1:150 dilution), mouse monoclonal anti-progesterone 
receptor-A and B, clone 1A6 (NovoCastra, Newcastle, UK; 1:50 dilution), mouse 
monoclonal anti-human COX-2, clone 4H12 (NovoCastra, Newcastle, UK; 1:50 dilution), 
mouse monoclonal anti-Mlh1, clone G168-728 (Cell Marque, Rocklin, California, USA; 
1:100 dilution) and mouse monoclonal anti-human Bcl-2 oncoprotein, clone 124 (Dako, 
Glostrup, Denmark; 1:100),   For IHC markers, glandular and stromal staining was recorded 
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using a semi-quantitative score (Q score).  The Q score is a validated scoring method that 
incorporates both the intensity and the distribution of specific staining and hence was 
preferred over H score.
108
  Intensity and proportion of stained cells were added for the Q 
score, which had a range of 0 to 8.  Two assessors carried out the Q scoring independently, 
blinded to the outcome.  The total proportion of cells staining positively at any intensity was 
scored as 0 (no cells staining), 1 (when <1% cells stained), 2 (when 1-10% cells stained), 3 
(when 10-33% cells stained), 4 (when 34-66% cells stained), or 5 (when 67-100% cells 
stained).  The intensity was scored according to the overall appearance as 0, none (no 
staining); 1, weak (only visible at high power magnification); 2, moderate (visible at low 
power magnification); 3, strong (striking even at low power magnification).  Two assessors 
carried out the Q scoring independently, blinded to index diagnosis and outcome.  Q score 
cut-offs were explored for all centiles and each of the biomarkers and two were reported with 
the lowest p value. 
   
Results 
During the study period we treated 196 women with LNG-IUS for CH or ACH and excluded 
women where material was not available for IHC (n=19) or was inadequate for scoring (n=3).  
The baseline characteristics of the 174 women included in our study are shown in Table 16.  
The median follow-up for all study participants was 72.1 months (IQR 59.1-89.8).  The 
agreement regarding histological scoring between the two histopathologists was 82.6% (K 
statistic = 0.801 ± 0.036).   
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Table 16 Baseline characteristics 
 
* Endometrial thickness was not measured in 21 women and BMI was not available in 7 women. 
 
The majority of study participants initially regressed to normal endometrium following LNG-
IUS therapy (n=164 regressed; n=10 persisted).  The women who had persisted EH: five 
demonstrated persistent hyperplasia of the same type, one upgraded from CH to ACH, four 
upgraded to well-differentiated FIGO Stage IA (n=2) or IB (n=2) EC.   From the 164 women 
that initially regressed with LNG-IUS we were able to assess 152 women for relapse as 11 
women declined long term follow up and one opted for hysterectomy. During follow up 18 
(11.8%) women relapsed for which 9 women had hysterectomy and one woman initially 
 
Persisted 
hyperplasia 
(n=10) 
Regressed 
hyperplasia  
(n=164) 
Age - <40 2 (20) 9 (5.5) 
 - 40-60 8 (80) 116 (70.7) 
 - >60 0  39 (22.4) 
Parity Nulliparous 3 (30) 33 (20.1) 
 1-2 children 2 (20) 74 (45.1) 
 >3 children 5 (50) 57 (34.8) 
Ethnicity White 6 (60) 136 (82.9) 
 Asian 1 (10)  16 (9.8) 
 Other 3 (30) 12 (7.3) 
Diabetes 2 (20) 30 (18.3) 
Hypertension 4 (30.8) 87 (36.7) 
Menopause 8 (80)  93 (56.7) 
HRT or Tamoxifen use 3 (30) 34 (24.7) 
Body Mass Index >35* 6 (60) 53 (33.8) 
Endometrial 
thickness>9mm* 
3 (33.3) 69 (47.9) 
Cytological atypia 5 (50) 14 (8.5) 
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diagnosed with CH progressed to endometrioid cancer with concomitant granulosa cell 
tumour of the ovary after 36 months from initial regression.  Relapse occurred in a median of 
32.2 months (IQR 11.3- 57.7).  
 
Table 17 Univariate analysis of Hazard ratios for the prediction of regression of endometrial hyperplasia when treated 
with LNG-IUS. (a) Centile cut-off with lowest p value (b) Centile cut-off with second lowest p value. 
 
(a) 
IHC markers 
 
Persisted 
hyperplasia 
(n=10) 
Regressed 
hyperplasia  
(n=164) 
Hazard ratio 
(95% CI) P value 
ER≥2 (5
th
 centile) 7 (70) 160 (97.6) 0.09 (0.01-0.39) 0.001 
PR≥2 (5
th
 centile) 8 (80) 159 (97) 0.32 (0.09-0.88) 0.02 
COX-2≥7 (75
th
 centile) 4 (40)  53 (32.3) 0.88 (0.72-1.38) 0.142 
MLH1≥6 (90
th
 centile) 5 (50) 69 (42.1) 1.52 (0.89-3.21) 0.276 
BCL-2≥6 (25
th
 centile) 8 (80) 129 (78.7) 1.33 (0.56-3.36) 0.162 
 
 
 
(b) 
IHC markers 
 
Persisted 
hyperplasia 
(n=10) 
Regressed 
hyperplasia  
(n=164) 
Hazard ratio 
(95% CI) P value 
ER≥4 (10
th
 centile) 6 (60) 151 (92.1) 0.19 (0.05-0.47) 0.008 
PR≥4 (10
th
 centile) 7 (70) 136 (82.9) 0.46 (0.17-0.91) 0.02 
COX-2≥3 (10
th
 centile) 10 (100)  154 (93.9) 1.49 (0.82-2.68) 0.189 
MLH1≥4 (75
th
 centile) 6 (60) 71 (43.3) 1.77 (0.89-3.45) 0.107 
BCL-2≥5 (10
th
 centile) 9 (90) 150 (91.4) 0.96 (0.82-1.23) 0.978 
 
The correlation of the baseline pre-treatment Q score and histological regression with LNG-
IUS therapy is depicted in Table 17.  Among women with CH or ACH at index biopsy, weak 
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associations were found for ER and PR expression on the 5
th
 and 10
th
 centile of the Q score 
and histological regression. COX-2, Mlh1 and Bcl-2 protein expression were not predictive 
of regression of EH.   The correlation of the baseline pre-treatment Q score and evidence of 
relapse with LNG-IUS therapy is depicted in Table 18.  Among women with CH or ACH at 
index biopsy, no associations were found between ER, PR, COX-2, Mlh1 and Bcl-2 protein 
expression and relapse of EH.   
 
Table 18 Univariate analysis of Hazard ratios for the prediction of relapse of endometrial hyperplasia when treated with 
LNG-IUS. (a) Centile cut-off with lowest p value (b) Centile cut-off with second lowest p value. 
(a) 
IHC markers 
 
Relapsed 
hyperplasia 
(n=18) 
Regressed 
hyperplasia  
(n=134) 
Hazard ratio 
(95% CI) P value 
ER≥2 (5
th
 centile) 14 (77.7) 115 (85.8) 0.38 (0.05-2.92) 0.354 
PR≥5 (25
th
 centile) 13 (72.2) 91 (67.9) 1.6 (0.36-7.1) 0.538 
COX-2≥5 (25
th
 centile) 15 (83.3)  95 (70.9) 2.89 (0.62-15.72) 0.157 
MLH1≥5 (50
th
 centile) 5 (27.7) 53 (39.6) 0.39 (0.19-1.27) 0.117 
BCL-2≥6 (25
th
 centile)  16 (88.9) 96 (71.6) 4.33 (0.56-33.45) 0.159 
 
 
(b) 
IHC markers 
 
Relapsed 
hyperplasia 
(n=18) 
Regressed 
hyperplasia  
(n=134) 
Hazard ratio 
(95% CI) P value 
ER≥4 (10
th
 centile) 14 (77.7) 110 (82.1) 0.56 (0.08-4.26) 0.572 
PR≥6 (50
th
 centile) 12 (66.7) 91 (67.9) 1.02 (0.35-2.98) 0.974 
COX-2≥6 (50
th
 centile) 15 (83.3)  97 (72.4) 2.37 (0.51-10.96) 0.269 
MLH1≥6 (75
th
 centile) 4 (22.2) 47 (35.1) 0.53 (0.17-1.81) 0.282 
BCL-2≥7 (50
th
 centile) 12 (66.7) 74 (55.2) 1.93 (0.25-14.87) 0.528 
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Figure 18 ER expression (Q score=8) for a woman that regressed with LNG-IUS treatment for complex endometrial 
hyperplasia.  
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Figure 19 PR expression (Q score=7) for a woman that regressed with LNG-IUS treatment for complex endometrial 
hyperplasia. 
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Figure 20 MLH1 expression (Q score=7) for a woman that regressed with LNG-IUS treatment for complex endometrial 
hyperplasia.  
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Figure 21 BCL2 expression (Q score=8) for a woman that regressed with LNG-IUS treatment for complex endometrial 
hyperplasia.  
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Figure 22 COX2 expression (Q score=8) for a woman that regressed with LNG-IUS treatment for complex endometrial 
hyperplasia.  
 
 
 
Discussion 
We publish the first large cohort study of women treated with LNG-IUS for CH or ACH 
assessing IHC predictors of regression or relapse. This study demonstrates that EH regression 
and relapse during follow up with LNG-IUS therapy is weakly associated with poor 
expression of ER and PR. COX-2, Mlh1 and Bcl-2 protein expression are not predictive.  
None of the biomarkers is predictive for relapse.   
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The results of this study are confirming our exploratory case-control study which found that 
the lack of ER and PR may predict women with persisting EH, but the predictive ability is 
attenuated .
117
  We have described that the case-control study design of our exploratory study 
has the risk of overestimating accuracy up to 3-fold by introducing spectrum bias.
116,117
  The 
cohort design of this study is the gold standard design to estimate the predictive ability of 
those markers and we believe our finding that these are poor predictors of important clinical 
outcomes in this context is likely to be reliable.  Our study is large but there were few events 
recorded as only 10 women had persisted hyperplasia and 18 relapsed.  The majority of the 
predictors reported in our study are not found to be associated with regression or relapse.  
However, our study is likely to be underpowered for avoiding type II error and there is a high 
likelihood that the predictors we have investigated may represent false negatives.
117,118
  We 
have also employed two assessors for scoring the IHC blinded to diagnoses and outcomes 
minimizing misclassification and observer bias. It is worth mentioning that in this study we 
used the outpatient endometrial sample as a monitoring tool. This is more acceptable to 
women inpatient and likely to be more accurate than ultrasound estimation of endometrial 
thickness, but there is no evidence assessing the monitoring value of these tools.  However, 
the LNG-IUS induces morphologic changes to the endometrium including glandular atrophy, 
stromal pseudodecidualization, and leucocyte infiltration. Glandular metaplastic changes, 
nuclear atypia and stromal myxoid change are also present and can pose significant 
diagnostic challenges during the histological surveillance.
119 
 
We have described previously the rationale for differential expression of ER and PR that 
could also contribute to the variation of efficacy in progestogen therapy of EH.  In the 
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literature, there are several studies investigating the ER and PR protein expression in EH 
treated with oral progestogens.
37-39
  These studies find conflicting and weak evidence that ER 
and PR protein expression may be predictive of outcomes in women treated with oral 
progestogens for EH.
37-39
  We have suggested that compliance with this therapy is an 
important confounding factor that is difficult to adjust for as it is difficult to measure.
116
  
With LNG-IUS therapy compliance is no longer an issue.  Despite abolishing this potential 
confounding the predictive ability of our IHC markers did not improve.  There are other 
molecular pathways (such as COX-2, Mlh1 or Bcl-2) that have been implicated in the 
generation of benign and malignant uterine pathology, but we did not find those to be useful 
predictors of regression or relapse of EH.   
  
Identifying women at higher risk of persistent or relapsed EH with progestogen treatment 
may have important implications for improving health outcomes for women with EH by 
improving patient selection for LNG-IUS therapy and ensuring closer endometrial 
surveillance for women at risk of treatment failure or malignant transformation.  We have 
found that obesity may be a strong predictor of women that relapse during follow up when 
treated with LNG-IUS.  This is important because relapse is common and women at low risk 
for relapse can be discharged from further follow up and women at high risk can have close 
surveillance to ensure they remain in regression.
8
  Possibly, because persistent hyperplasia is 
less common (about 10%) with LNG-IUS it may be unlikely that we find an IHC predictor 
that will raise the probability of persistent hyperplasia so high that clinicians would not opt to 
try LNG-IUS treatment.  On the other side, if a predictor can ensure that these women almost 
certainly are going to respond to treatment this will not change clinical practice.  Clinicians 
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would wish to have histological evidence of regression of EH and would follow up women 
until regression is proven.  
 
Further research from other groups is needed to validate our findings from this study.  
Nonetheless, we believe this study may shape future research on the identification and 
evaluation of a clinical prognostic model for EH in order to improve health outcomes 
associated with this pre-malignant condition.  Such a model may incorporate and integrate 
biodemographic parameters (e.g. age, BMI, parity), histological cyto-architecture 
classification and molecular phenotyping.  Furthermore, this model is likely to be more 
clinically useful if it identifies accurately women likely to regress and not relapse during 
follow up who can be safely reassured.   
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Chapter 10: Conclusions & Recommendations 
Summary of findings 
We have made a significant contribution to improve the management and prognosis of EH 
through the findings from this thesis.  Our findings, but also the important limitations are 
summarised per Chapter below: 
 
Chapter 1 
In this Chapter we have discussed the definition, risk factors, classification and prior 
knowledge for the management and prognosis of EH.  This was important to identify gaps of 
knowledge and make a significant contribution where is required.  We have proposed a 
simplified version of the WHO classification and disseminated the advantages of omitting 
SAH, which is of disputed existence and created confusion among clinicians because of the 
uncertainty in its management. 
 
Management of EH 
Chapter 2  
In Chapter 2 we searched and meta-analysed the regression rates recorded in observational 
studies with the most popular conservative therapies for EH.  We compared the regression 
rates, defined as conversion of CH or ACH to simple hyperplasia or proliferative 
endometrium and proliferative endometrium from SH, achieved by the LNG-IUS and oral 
progestogens for each type of EH.  We found that for CH and ACH the regression rates for 
LNG-IUS were high and significantly higher compared to oral progestogens.  There was no 
statistical difference in simple hyperplasia. We found only small case-series of poor quality 
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predominantly for evaluating the regression rates, which we summarised and indirectly 
compared reducing the accuracy of the estimated regression rates. 
 
Chapter 3  
In this Chapter we investigated the regression, relapse and live birth rates with fertility-
sparing treatment for ACH and EC.  Fertility-sparing treatment for EC achieved a high 
regression rate with an encouraging live birth rate. For ACH the pooled regression and live 
birth rate was even higher. However, for both conditions we observed a high relapse rate of 
the disease, defined as relapse of ACH or EC during follow-up.  We also found that diagnosis 
of ovarian cancer (concurrent or metastatic) during follow-up, progression of the disease and 
even death are both risks of this approach. Similarly to Chapter 2, we found only small case-
series with short follow-up predominantly for evaluating the regression, relapse and live birth 
rates, which we summarised and indirectly compared reducing the accuracy of the estimated 
rates.  
 
Chapter 4  
From this Chapter we summarised the current clinical practice of managing EH.  We 
presented to Gynaecologists nationally the observational findings and enquired whether 
future research would improve the management of this condition.  We found that most 
clinicians treat CH with LNG-IUS or oral progestogens and ACH with hysterectomy.  
Despite LNG-IUS appearing to be more effective in treating EH clinicians used equally 
LNG-IUS and oral progestogens and would wish more research on the effectiveness of these 
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therapies. The response rate to this survey was low and selection bias threatens the internal 
validity and precision of the results.  
 
Chapter 5  
In this Chapter we analysed our findings from the largest cohort study in the literature with 
long-term follow up.  We found that women treated for CH and ACH with LNG-IUS and 
compared their regression and hysterectomy rates to oral progestogens.  We found that 
regression, as defined before, is more likely with LNG-IUS and hysterectomies are less when 
compared to oral progestogens.  We defined the time to regression and defined the EC risk 
for women that fail to regress. However, the observational design cannot exclude residual 
confounding from unmeasured variables and follow-up differed in the two groups with the 
retrospective inclusion of women treated with oral progestogens introducing performance and 
verification bias. 
 
Chapter 6 
Following up our cohort from Chapter 5 we defined the relapse risk for women that initially 
regressed with LNG-IUS or oral progestogens.  We obtained more than five year follow up 
for all women.  We found that relapse of CH and ACH after initial regression, defined as 
relapse of CH during follow-up, occurs often but it occurs less often in women treated with 
LNG-IUS than with oral progestogens.  We also calculated the time to relapse and the EC 
risk for women that relapsed during follow up.  The follow-up was adequate reducing 
attrition bias, but differed in the two compared groups with the retrospective inclusion of 
women treated with oral progestogens introducing performance and verification bias.  
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Prognosis of EH 
Chapter 7 
Our first study on the prognosis included in this Chapter generated the hypothesis that 
women who fail to regress after treatment with LNG-IUS may be predicted from ER and PR 
status on the index endometrial biopsy.  Neither PTEN nor aromatase expression were 
associated with LNG-IUS therapy responsiveness.  These results were encouraging but 
needed further testing on prospective cohort study. However, the size was small, the estimate 
was likely to be unstable and the case-control design overestimated the accuracy of the 
biomarkers.  
 
Chapter 8 
 In this Chapter we investigated the prognostic ability of clinical characteristics to predict 
regression and relapse for women treated for EH with LNG-IUS or oral progestogens.  We 
found that BMI is a strong independent predictor of relapse but no predictors were found to 
be independent for the outcome of regression. This study was larger than Chapter 7 and likely 
more accurate because of the cohort design, but still had less than 80% power for avoiding 
type II error.  
 
Chapter 9  
From this Chapter we wished to complement our prediction model from the previous Chapter 
and improve its accuracy for women treated with LNG-IUS.  We found that ER, PR, COX-2, 
Mlh1, and Bcl-2 expression is not predictive of regression or relapse in women with 
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endometrial hyperplasia treated with LNG-IUS. Likewise, this study was larger than Chapter 
7 and likely more accurate because of the cohort design, but still had less than 80% power for 
avoiding type II error.  
 
  
Chapter 10  
In our last Chapter we summarise our findings and make recommendations for clinical 
practice.  Our recommendations become an essential part of a national guideline endorsed by 
the RCOG for the management and prognosis of EH, which is still in process.  Our 
recommendations are summarised in the next section.  
 
Implications for clinical and research practice 
In this section we summarise the implications for clinical practice from the findings 
discussed previously.  Those are summarised per chapter below: 
 
Chapter 1 
From this Chapter our simplified version of the WHO classification and disseminated 
through our guideline group and publications will improve the management of EH by 
omitting a dubious group of uncertain significance.  
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Management of EH 
Chapter 2  
From this research by defining the regression rates for LNG-IUS and oral progestogens we 
are empowering the counselling of women with EH by providing the effectiveness 
information and improve clinician knowledge.  Improving clinician knowledge and 
confidence in these therapies can reduce unnecessary hysterectomies.  
 
Chapter 3  
From this Chapter we offer clinicians excellent information for counselling these women 
with an early clinical stage of ACH and EC and an evidence-based approach in their 
management. The editors of the American Journal of Obstetrics & Gynecology also 
highlighted this contribution in their commentary on our article, which was their choice for 
the respective issue.  
 
Chapter 4  
This Chapter is likely to have indirect implications in practice as clinicians may chose to 
amend their practice by reproducing the practice of the majority of the clinicians. 
 
Chapter 5  
From this Chapter we have contributed the largest cohort enforcing the efficacy of LNG-IUS 
treatment over oral progestogens. By defining the time to regression and the EC risk in 
women that fail to regress we recommend a clear window in which LNG-IUS or oral 
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progestogen treatment is expected to have the desired effect of endometrial regression 
maintaining women safe from disease progression. 
 
Chapter 6 
From this research in Chapter 6 we expect a major change in current practice.  Clinicians 
discharge women from further follow up following initial regression with LNG-IUS or oral 
progestogens but are likely to change this practice because of the relapse risk.  Relapse is 
very common and the progression to EC is significant warranting further surveillance.  We 
have made clear recommendations from our research how long women should be followed 
up based on our findings, while appreciating the limitations of differences in follow-up 
between the two treatment groups. 
 
Prognosis of EH 
Chapter 7 
Our study generated the hypothesis ER and PR need further evaluation as they constitute 
good predictors of persistent EH with LNG-IUS and encouraged research for testing this 
hypothesis.  
 
Chapter 8 
 This Chapter has major implications for clinical practice as Chapter 6.   BMI is found to be a 
strong independent predictor of relapse and we have recommended that women without this 
exposure can be safely discharged from further follow up and women with this exposure 
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should be followed up over the long term as almost one out of three is likely to relapse.  We 
have made recommendations on the duration of follow up based on our findings. 
 
Chapter 9  
This Chapter has great implications for future research.  The predictors we have studied were 
investigated from several research groups with conflicting findings.  We found them to be 
poor predictors in the largest cohort study described in the literature and our results are likely 
to be reliable even though not excluding completely a type II error.  Researchers were 
recommended to investigate novel markers for outcomes of EH and especially for relapse, 
which has major implications on following up women over the long term and it can 
complement the prognostic accuracy of BMI. 
  
Chapter 10  
Our recommendations through a national guideline endorsed by the RCOG for the 
management and prognosis of EH, will have a great impact on the clinical practice because of 
widespread dissemination and improved reliability.  
 
Recommendations for further research 
- The difference in regression and relapse rates for LNG-IUS and oral progestogens is almost 
undisputable for many clinicians.  A recent application for funding of a randomised trial was 
rejected because of concerns over recruitment and we believe that equipoise for a randomised 
trial between the two may not be there anymore and prospective cohort studies from other 
142 
 
centres are advised to prove the reproducibility of our findings.  An update for this systematic 
review is required now to integrate our studies. 
- Similarly, our findings for women with ACH and EC need to become more robust by 
integrating more studies.  This will improve reliability and an update of the systematic review 
is recommended in 1-2 years. 
- With our research we may have contributed to a change in practice of many clinicians who 
will now prefer LNG-IUS over oral progestogens for EH.  A further national survey showing 
this shift in practice will convince researchers that a randomised trial between those may not 
be longer feasible.    
- Our cohort study needs to continue the follow up and our database interrogated again at 10 
year follow up.  This will provide unique data in the literature for the effectiveness of LNG-
IUS and oral progestogens along with improving our understanding of the natural history of 
the disease. 
- Further research is needed to indentify novel predictors of relapse to improve the accuracy of 
BMI.  This will result in less women being followed over the long term and reduce NHS 
costs. 
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Metchley Park Road 
                Edgbaston 
PATIENT INFORMATION LEAFLET           Birmingham B15 2TG 
PATIENTS CAN KEEP THIS LEAFLET                                                         Switchboard:  0121 472 1377 
                                                                                                                                                                                                                     
RESEARCH INTO BENIGN GYNAECOLOGIC CONDITIONS 
 
Invitation to help 
We would be grateful if you would consider participating in a research study to help us find out why women 
develop endometrial hyperplasia (thickened lining of the womb) and/or abnormal vaginal bleeding and 
identify the best cure.  Birmingham Women’s Hospital and Wellbeing of Women funds this study.  Before 
you decide whether to take part, it is important for you to understand why the research is being done and 
what it will involve.  Please take time to read the following information carefully and ask a member of the 
research team if anything is not clear. 
 
What is the study about? 
This research will analyze biopsies (tiny samples of tissue removed from the womb) of women with 
endometrial hyperplasia and/or abnormal vaginal bleeding.  We intend to find out what genes are involved 
and their relation to hormones as a cause of these conditions, success of treatment or eventual failure.  
This research will help us to understand the causes and thereby enable us to develop better therapies. 
    
Why have I been chosen? 
Your doctor informed you that you have thickened lining of your womb (endometrial hyperplasia) and/or 
abnormal vaginal bleeding (heavy and/or irregular periods or bleeding after menopause). 
 
Do I have to take part? 
Not at all.  It is entirely up to you whether or not to take part in this study.  You do not have to take part, or 
give a reason if you choose not to.  Your decision will not affect your care or treatment in any way now, or in 
the future.  
If you decide at any point to withdraw your consent for your samples to be used for research purposes, 
please contact us (contact details below), and your samples will be disposed of in a respectful manner.  
However results from research already carried out using your samples may still be used. 
 
What will I have to do?  
If you agree, you will be asked to sign a consent form.  You should only do this if you are happy that you 
understand the project and want to take part.  
When you come to the clinic, your doctor might require taking an endometrial biopsy (about 1cm3; the size 
of a peanut).  We would like to use part of this sample for research.  In case you have any endometrial 
biopsies already taken and stored in our laboratory we would like to use them for this study as well.  Your 
participation in this study will not affect the management of your condition in any way. 
 
Will I need to have an extra biopsy if I participate in this study?  No 
We will use a tiny piece from the biopsy taken by your doctor in clinic.  Only in case you have a 
hysterectomy (surgical womb removal) we will take an extra biopsy while you are under anaesthesia or 
after removal of your womb.  We will obtain the endometrial samples when you attend for your 
Gynaecology Outpatient clinic, Hysteroscopy clinic or during your Gynaecology theatre operation.  
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How will you obtain the endometrial biopsy sample? 
The sample will be taken by a narrow plastic straw, which is inserted into the neck of the womb (cervix) and 
works by gently suctioning the cells that line the inside of the womb.  We can show you this device if you 
wish before the procedure for reassurance.  Usually the procedure takes around 10 to 20 seconds. 
 
What happens to the endometrial biopsy sample after it has been taken? 
This sample is sent to the Hospital Histopathology laboratories for routine analysis.  We will also take a tiny 
part of the sample and analyse this separately in our own University research department.  Your sample will 
be stored at the University of Birmingham and will only be analysed by the recognised researchers involved 
in this project.  The project has undergone a strict approval procedure and has been reviewed by an 
independent committee.  Ethical approval will again be sought before any additional studies are performed 
on your samples. 
  
What are the benefits of taking part? 
There will be no overall benefit for you in taking part in the study.  However this study will help our 
understanding of why women develop endometrial hyperplasia and will hopefully lead to improvement in 
diagnosis or treatment of this condition.   
 
What are the risks? 
There are no risks involved in taking part in this study. 
 
What will happen to the information? 
All of your samples will be given a unique code that protects your identity.  This code will be used in all 
experiments and for the analysis of data.  We will keep a record that links the unique code for your sample 
back to you.  This is so that when we analyse the data we can correlate the results with clinical information. 
This is scientifically useful.  The link back to your identity will be kept within the hospital so that no-one 
outside your healthcare team can see your medical records.  All information about you, and any results, will 
remain confidential.  With your consent, your General Practitioner will be informed of your participation. 
 
Who should I contact if I have a complaint? 
If you have a complaint and wish to contact someone who is not involved in the study you can contact the 
PALS (Patient Advice and Liaison Service) an independent service set up to help patients resolve any 
problems or concerns they may have.  This is a confidential service and can be contacted by ringing: 0121 
507 5836 (9am-5pm Monday to Friday). 
 
Can I ask more questions about the study and procedure? Yes.  
At any time we can answer any questions you may still have; if necessary you can contact any one of the 
study co-coordinators for further information.  
 
Study coordinators at Birmingham Women’s Hospital 
Prof. Janesh Gupta, Consultant Gynaecologist   (Tel: 0121 607 4751)   
Dr. Ioannis Gallos, Research Fellow    (Tel: 0121 607 2702) 
 
http://www.wellbeingofwomen.org.uk/research/grants-awarded/2008-grants/?art=214  
 
 
Many thanks for your time and help 
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Metchley Park Road 
Edgbaston 
Birmingham B15 2TG 
Switchboard 0121 472 1377 
 
 
PATIENT CONSENT FORM FOR RESEARCH INTO BENIGN GYNAECOLOGIC CONDITIONS 
 
Please initial each box if you agree with the statement. 
 
1. I confirm that I have read and understand the information sheet dated 9th April 2009 (version 2) 
and had an opportunity to ask questions. 
2. I understand that my participation is completely voluntary and that I am free to withdraw at any 
time, without giving a reason and without prejudice to myself.  
3. I agree to take part in the above study and will donate a part of biopsy tissue.  
 
4. I agree for my tissue already collected and stored to be used in this study. 
 
5. I agree that my tissue may be stored for future research, including genetic studies, providing 
ethical approval for these additional studies has first been obtained. 
 
6. I agree that my identifiable data may be stored by the principal investigator but  
 it will not be passed on to any persons outside of the research group. 
 
7. I agree for my General Practitioner to be informed of my participation in this study. 
 
 
Volunteer Printed Name…………………….…………… Signature……..………..………Date……………………..
     
 
Doctor (Investigator) Printed name………………….……… Signature…………………….……Date…………………….….
  
 
Independent witness (Nurse) Printed name………………....Signature……………………..……Date………………………… 
   
 
You can contact any one of the study coordinators for further information. 
Prof. Janesh Gupta, Consultant Gynaecologist   (Tel: 0121 607 4751) 
Dr. Ioannis Gallos, Research Fellow                    (Tel: 0121 607 2702) 
 
This is for information only; please do not sign this form. 
